African Leaders Declare End of Aid Era at Nairobi World Health Summit, But The Data Tell a More Complicated Story 29/04/2026 Stefan Anderson Delegates gather for the opening plenary of the World Health Summit Regional meeting in Nairobi, Kenya. African leaders opened the World Health Summit Regional Meeting at the United Nations complex in Nairobi this week with a unified declaration that two decades of dependence on foreign aid for health is over. “The challenge that I see is that many of the leaders in our continent believe that it is somebody else’s responsibility. It should be the World Health Organization, USAID, I don’t know who,” Kenyan President William Ruto told the summit. “The sooner we realise that it is our responsibility to raise especially domestic resources to fund our health, the better for all of us.” The Nairobi meeting, the first co-organised by the World Health Organization (WHO) and the World Health Summit, has positioned itself as the continent’s first high-level response to the collapse of official development assistance (ODA) for health, which fell by an estimated $31.1 billion in 2025, according to the Africa Centres for Disease Control and Prevention (Africa CDC). Over 2,000 delegates from more than 50 countries, including health and finance ministers from 17 nations, are convening in the Kenyan capital to coordinate a united African position ahead of next month’s World Health Assembly in Geneva. “I don’t want to see this continent being dependent. And we are dependent because we want it,” Ruto said. “Africa is manufacturing a number of products today, from Egypt, from Kenya, from South Africa, from a number of countries, but we are not buying our own product.” Africa carries more than 25% of the global disease burden but accounts for less than 3% of global health expenditure. The continent currently produces less than 2% of the medicines and vaccines it consumes, leaving its countries dependent on external supply chains for essential medical commodities. “Who’s asking us not to buy our own product, who’s asking us not to register to the African Medicines Agency for the regulatory aspect?” Ruto asked. “It’s not Germany, it’s not Europe, it’s ourselves. We need to change our mindset.” A break with the past African leaders led by Kenyan President William Ruto arrive in Nairobi for the summit. The urgency on display in Nairobi is driven by the most disruptive year for global health financing on record. For African governments, the pivot to self-reliance has become a fiscal necessity. The dismantling of the United States Agency for International Development (USAID), followed by aid cuts by the United Kingdom, Germany, France and the Netherlands, drove a 23.1% drop in total ODA from OECD donors in 2025. This is the largest single-year contraction since records began. The US, Germany, UK, Japan and France accounted for 95.7% of the total decline. The Boston University ImpactCounter estimates the US cuts have already led to more than 518,000 child and 263,000 adult deaths from preventable diseases such as HIV and tuberculosis. A further 14 million preventable deaths, including 4.5 million children, may occur by 2030 if USAID funding gaps are not filled, a major international study found. Africa CDC estimates the combined cuts from the US, UK, Germany and other major donors will kill an additional two to four million Africans annually. “The year 2025 marked the end of one era and the beginning of another,” Sulaiman Shahabuddin, President and Vice Chancellor of the Aga Khan University, told the opening plenary. “We are confronting a new reality, defined by funding constraints, the rise of technology and artificial intelligence, and a decisive shift towards local ownership.” “Climate change, chronic diseases, lack of financial resources, the digital divide, inequity and others are [challenges] we will have to overcome,” Shahabuddin added. What aid remains on the table increasingly comes with strings attached. Washington has begun rolling out bilateral “America First” global health agreements, with US President Donald Trump retaining the right to terminate any programme judged not to align with American interests. Conditionalities include sharing pathogen samples and genomic data with US authorities, prioritising faith-based health providers to prevent services such as abortions, channelling funding away from non-governmental organisations, and, in the case of Zambia, granting access to critical minerals in exchange for health funding. Lukoye Atwoli, Dean of the Aga Khan University Medical College East Africa and the summit’s international president, said this year’s gathering would mark a break with past meetings on African health. “Historically, meetings about Africa and Africa’s health have been about lamentations. Have been about framing the problems. Have been about basically begging and saying that we have a problem and we need help,” Atwoli told delegates. “This meeting will be different.” Reform body launched Africa CDC Director Dr Jean Kaseya speaking in Nairobi. On the sidelines of the summit, Africa CDC launched the African High-Level Ministerial Committee on Global Health Architecture Reform. The body brings together health and finance ministers from across the continent to coordinate African positions ahead of the World Health Assembly and broader UN reform processes. Convening both portfolios in the same room is a long-standing demand of global health advocates, who have struggled for decades to make the economic case for health investment to treasuries that hold the purse strings. The committee, chaired by former Liberian president Ellen Johnson Sirleaf, will produce coordinated African position papers on health architecture reform and a 2026–2030 reform roadmap focused on five axes: governance, financial sovereignty, data sovereignty, local manufacturing, and pandemic preparedness. “The old model is no longer fit for purpose. Africa cannot continue to be a passive recipient of global health decisions,” said Africa CDC Director General Dr Jean Kaseya. “We welcome our partners, but on a new basis: not as donors and recipients, but as equal partners aligned with Africa’s priorities.” Aspiration meets evidence Official development assistance fell by a historic 23.1% in 2025. African nations are among the hardest hit. The data on whether Africa can deliver on the vision laid out in Nairobi tell a more complicated story. A Centre for Global Development (CGD) audit of 442 government actions across all 54 African countries found a continental reaction to the historic aid cuts split in radically uneven ways, a story of inequality within Africa as much as between Africa and its donors. The countries that moved fastest are those with the deepest pockets and most diversified economies, including Nigeria, Ghana and Ethiopia. Lower-income, debt-burdened countries, many of which were the largest per-capita recipients of foreign assistance, have largely absorbed the loss in silence. “Governments with limited fiscal space and weaker administrative capacity have less room to cushion abrupt external shocks,” the analysis found. “What is slightly surprising is that they were not only doing little about the aid cuts, they are also saying little about them.” Global Health Leaders Urge Fewer Agencies Amid Funding Crisis A separate CGD study published in February examined the budget statements of 18 sub-Saharan African countries: among the world’s poorest, most heavily aid-dependent and exposed to the cuts. It found that only two, Tanzania and Sierra Leone, proposed new revenue measures to replace lost financing in their 2025 budgets. None reprioritised spending from other sectors to protect health. “With few exceptions, governments neither raised new revenues nor reallocated spending to compensate for lost external financing,” the analysis concluded. The burden of adjustment, it found, has instead fallen on the services patients receive, from disrupted HIV and tuberculosis treatment to delays in vaccination campaigns and the closure of clinics that depended on donor financing. “Health is not a cost, it is an investment,” Ruto said. “And it is important for us to invest.” Cascading crises Runaway climate change is colliding with constant economic shocks from war and the COVID-19 pandemic, shrinking Africa’s budgets and taking away the space to invest in health. The continent’s ability to absorb the aid shock and finance the pivot to support its own health systems is constrained by an unending sequence of external crises over the past decade that continue to batter government budgets, layered on top of the escalating climate crisis. The COVID-19 pandemic, during which wealthy nations hoarded vaccines, exposed Africa’s reliance on a foreign supply chain that produces 99% of the vaccines and 90% of the medical supplies it consumes. Pandemic response cost African governments an additional $154 billion in 2020 and 2021, according to the African Development Bank, pushing sub-Saharan public debt up by 8 percentage points of GDP in a single year. Russia’s invasion of Ukraine drove an inflationary spike that ballooned debt-service costs across the region, a pressure that has now snowballed into the global economic crisis triggered by the US-Israeli war on Iran, to which African economies are uniquely vulnerable. The closure of the Strait of Hormuz, a chokepoint for a fifth of the world’s oil and a third of its liquefied natural gas, is driving up fuel and fertiliser costs and deepening food insecurity across the continent. The resulting inflation, weaker currencies and tighter global financial conditions across Africa are inflating debt-servicing bills and forcing governments to divert money that could otherwise help absorb the aid shock. Climate change is compounding the pressure on every front. African countries are losing between 2% and 5% of GDP to climate extremes, the World Meteorological Organization estimates, with some governments diverting up to 9% of national budgets to respond. Health systems will bear a growing share of that cost. The World Bank estimates climate change could drive at least $21 trillion in excess health costs in low- and middle-income countries by 2050, with sub-Saharan Africa among the regions hit hardest. “What was considered reliable for decades is turning out to be fragile,” said Birgit Pickel, Director-General for Global Health at Germany’s Federal Ministry for Economic Cooperation and Development. “Cracks are appearing in the international order. Cracks that, in some cases, are already leading to its collapse.” Fiscal squeeze limits options African debt levels have more than doubled in the past decade, according to ONE Data figures. The cumulative damage has left African governments with little room to manoeuvre. Thirty-two African nations now spend more servicing external debt than funding healthcare. The continent paid almost $90 billion in external debt service in 2024 alone, with African governments now spending an average of 17% of state revenue on debt servicing, according to leading estimates. The IMF warned last week that more than a third of African countries are at high risk of, or already in, debt distress, with rising interest bills “crowding out essential development spending, healthcare above all.” “Official funding will probably shrink, at least internationally. Domestic funding will hopefully move up,” Pickel said. “But there are innovative instruments out there to also meet urgent funding needs in the health sector, especially for heavily indebted countries.” Pickel proposed debt-for-health swaps, an instrument under which creditor nations cancel debt in exchange for redirected health spending, as a route to fiscal space for highly indebted countries. Germany issued €100 million in such swaps last year, channelled to the Global Fund. The figure is substantial as a signal, but negligible against the scale of the African external debt service crisis. The IMF’s Africa Director, Abebe Selassie, told the Fund’s Spring Meetings in Washington this month that the 2025 foreign aid contraction marks a structural break – and the money is unlikely to come back. “Past aid shocks were largely cyclical; donors cut back and then returned. What we are seeing now appears more structural,” Selassie said. “And it is falling hardest on the region’s most vulnerable countries: fragile states and low-income economies that depend on aid not as a supplement, but as a critical source of budget financing, healthcare, and food assistance.” The summit runs through Wednesday, with the African Union expected to publish a position paper on global health architecture reform at its close. Image Credits: ONE Data. Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Making Better Vaccine Choices in a Shifting Global Health Landscape 27/04/2026 Charlie Weller A baby gets a first dose of the measles, mumps and rubella (MMR) vaccine at a health center in Côte d’Ivoire. Global aid cuts have left countries struggling to meet childhood vaccine schedules. In an era of big global health budget cuts that often demand tough choices, identifying vaccine needs and priorities at national level is increasingly important. As we observe World Immunization Week, it’s time to recognize the pivotal role that National Immunization Technical Advisory Groups (NITAGs) can play in guiding effective, evidence-based decisions – alongside global guidance from the World Health Organization. From infancy to old age, vaccines are a life-saving tool. Over the past 50 years, vaccines have saved more than 150 million lives. They play a decisive role in keeping us safe from diseases through childhood, strengthening our immune responses in adulthood, and keeping us out of hospital in our older years. Immunisation currently prevents 3.5 million to 5 million deaths every year from diseases like tetanus, pertussis, influenza, and measles. Without vaccines, diseases consigned to the past could resurge in our present. Funding cuts and reduced resources are increasing barriers to vaccine research and development, as well as equitable access to immunisation – including the routine vaccination of young children in low- and middle-income countries. This reduction in support and resources is forcing organisations like the World Health Organization and Gavi, the Vaccine Alliance, to rethink how they operate. Vaccine decision-making is no longer about access alone; it’s about prioritisation under constraints. (Left to right columns). Deaths averted, years of life saved, and years of full health gained due to vaccination. From global guidance to national decision-making Many countries still rely heavily on vaccine recommendations made by the WHO through the Strategic Advisory Group of Experts on Immunization (SAGE). While being scientifically robust and relevant they do not always reflect the specific needs, challenges or health systems of individual countries. With global health funding undergoing dramatic reductions, countries and regions most affected by infectious diseases are facing difficult decisions about which diseases to prioritise and how best to procure and roll-out vaccines to maintain even fuller vaccination schedules. This greater emphasis on country-level decision-making is appropriate – countries affected by diseases are best placed to make decisions on how to tackle them. However, it takes time to build expertise and evidence, and responsibility is being decentralised faster than this capacity can be developed, with experts required to wear multiple hats. This is not merely a technical challenge, but a political and operational one. It requires a reshaping of power and accountability in global health structures. filling gaps in infrastructure to support more national and regional decision-making. SAGE Executive Secretary Joachim Hombach presents updates on WHO vaccine recommendations at a 2025 briefing. While such global guidance remains critical, a greater emphasis on country-level decision-making is also appropriate. Regional decisions need regional expertise Building regional sharing of expertise is now as critical as supply chains. This is where advisory groups such as the National Immunization Technical Advisory Groups (NITAGs), can play a pivotal role in guiding effective, evidence-based decisions. Each country’s NITAGs expertise differs, but their aim is the same – multidisciplinary independent experts assess whether international knowledge is applicable and relevant to local contexts, informing appropriate policy recommendations at a national level and bridging the gap between research and policy action. The impact of NITAGs can be felt quickly, allowing the introduction of specific vaccines that better suit the regional needs – whether it’s switching from one malaria vaccine to another in Nigeria, or the introduction of a Hepatitis B vaccine given at birth in Lesotho. For this model to work effectively, sustained funding is needed not just for research projects but to support policy-relevant expertise, enabling research to be translated into country-relevant recommendations. This is why Wellcome is investing in the African-led NITAG Support Hub, or NISH, which helps strengthen NITAGs across Africa. Through local evidence and support, and by sharing expertise and best practice via resource hubs, countries can be better prepared to navigate choices, including which of the increasingly robust array of lifesaving vaccines to prioritise, where, and how – all whilst aid and global health budgets are shrinking. Similarly, Gavi, The Vaccine Alliance has introduced ‘The Gavi Leap’ – a new operating model aiming to support country self-reliance to transition away from donor-led systems. Gavi Leap is increasing resources to help countries decide their own priorities, financing and delivery of vaccines with the long-term goal of immunisation sustainability. The intervention trade-offs A Kinshasa neighbourhood water point in DR Congo. Better WASH practices can complement cholera vaccination efforts in fighting the deadly disease. Amidst global instability, decision-makers increasingly need to balance the benefits of investing in one vaccine over another, as well as balancing the costs of vaccine procurement and distribution with spending on other interventions such as diagnostics and therapeutics, surveillance and health system strengthening. For example, while oral cholera vaccines alone protect individuals against the disease, and water, sanitation and hygiene (WASH) alone reduces the amount of bacteria in the environment, studies suggest that combining the oral cholera vaccine with improved household WASH leads to optimal protection. Oral cholera vaccination campaign in Democratic Republic of Congo, December 2023. There is a tricky balance to strike, taking into account factors such as available resources; behavioural attitudes to interventions; the benefits and risks of mass immunisation campaigns; and the needs of vulnerable, under-resourced communities. And any public health policies must take a long-term view, with the ability to adapt to changing circumstances – such as the emergence of new outbreaks, new pathogen variants, and new forms of disease resistance. Diverse expertise combined with awareness of local needs and barriers is essential to ensure vaccines are neither over-prioritised nor underused. Global health will, and must, be a global effort, and international guidance remains essential. But it cannot replace regional and national judgement and local knowledge of community needs and challenges. Investment in expertise means equitable vaccine policies With tightening global funding, choices between vaccines and other essential health interventions are unavoidable. Doing so without investment in more localised expertise is not. Investing in national and regional advisory capacity, knowledge-sharing and long-lasting expertise is not a luxury, it is the foundation of smarter, fairer vaccine decisions in an increasingly constrained world. Charlie Weller is the Head of Prevention in Wellcome’s Infectious Disease team. Since 2016, she has led the team to develop new and improved vaccines and antibodies – from managing the research and funding response to the Ebola epidemic of 2014-2015, to helping the co-founding of the Coalition for Epidemic Preparedness Innovations (CEPI), which is investing in new vaccine development that protects the world from epidemic and pandemic threats. Image Credits: UNICEF, Shattock A, Johnson H, Sim S et al.,The Lancet, May 2024, E. Fletcher/Health Policy Watch , Eduardo Soteras Jalil/ WHO, Esther Nsapu/Wellcome Trust. UN Deadlock and Iran War Oil Shocks Push 54 Nations to Chart Fossil Fuel Phase Out 27/04/2026 Stefan Anderson Governments, civil society and indigenous communities gather in Santa Marta Colombia to address the hurdle decades of UN climate summits have failed to clear: phasing out fossil fuels. More than 50 countries are gathering this week on Colombia’s Caribbean coast to launch a coalition for phasing out fossil fuels, as a third month of war in Iran exposes the costs of a global economy run on the oil, gas and coal driving the climate crisis that decades of deadlocked UN climate talks have failed to curb. No outcome text, funding or binding legal commitments are expected to come out of Santa Marta. Yet that the meeting exists at all – and is attended by several major fossil fuel powers including Australia, Canada, the United Kingdom, Nigeria and Norway – is a source of optimism for observers hoping it may be the start of a wind change in climate politics. The final tally of 54 states attending the first-of-its-kind conference is more than double the number of founding signatories who joined Colombia’s initiative as UN climate talks collapsed at COP30 in Belém last November. Combined, the coalition in Santa Marta represents around half of global GDP and 2.5 billion people, roughly a third of the global population. “The task for those attending is clear: not to debate whether to phase out fossil fuels but to determine how to do it – rapidly, fairly, and in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. “It has never been more urgent to leave behind oil, gas and coal than it is today.” Climate Change Is Here, And It’s Killing Millions Ministers and high-level delegations arrive on Tuesday and will negotiate through Wednesday evening. The primary goal, its host Colombia said, is “to launch an international coalition to jointly implement the transition away from fossil fuels.” “We need a multilateralism that is more deeply rooted in the people and not just in governments, biases or economic lobbying,” Colombian environment minister Irene Velez-Torres told AFP. “We need new alignments, new alliances. In that sense, we are a new power today,” she said, pointing to the global coalition in attendance. Fossil fuels are also driving a mounting public health catastrophe. Heat exposure now claims an estimated 546,000 lives annually, while air pollution from burning oil, gas and coal kills another 2.5 million people each year, according to the Lancet Countdown on health and climate change. “Fossil fuels are causing immediate harm,” said Jeni Miller, executive director of the Global Climate and Health Alliance, a consortium of more than 250 health organisations that submitted recommendations to the conference. “Phasing them out is not only about protecting the planet but also about saving lives in the near term, reducing strain on health systems, and creating greener, more just, and healthier societies.” The talks will aim to allow space for constructive negotiations among like-minded nations, unencumbered by the consensus-based UN system. Agreements at COPs require all 200 nations to sign off on the final text, a system which has allowed petrostates to block progress for decades. “The consensus methodology has resulted in a de facto veto against countries like Colombia that want more ambitious discussions on decisions, particularly related to fossil fuels,” Velez-Torres said. Who’s at the party? Boats sit along the Caribbean coastline of Santa Marta, Colombia, host city of the conference. Participants in Santa Marta include the European Union, the United Kingdom, small island developing states on the frontlines of sea level rise, several dozen developing nations, and COP31 co-hosts Turkey and Australia. Organisers said more than 2,600 civil society and indigenous community representatives are also in attendance in-person and online. Fossil fuel superpowers in the Gulf, the United States and Russia are not present. The world’s other biggest emitters including China, India, Iran and Japan, will also be absent. But unlike UN proceedings, which invite all member states by default, the tone struck by Colombia and the Netherlands is different: if you’re not going to help, don’t come. “We are not going to have boycotters or climate denialists at the table,” Vélez-Torres told the Guardian. “Whatever nations have not yet taken that decision, then this is not the space for them.” “Despite our differences, all participants agree on the need to prioritise science and to move forward, urgently and in a coordinated manner, toward phasing out the production and consumption of natural gas, coal, and oil,” she added in a statement shared by the summit presidency. The United States, for example, was not even invited. The Trump administration declined to send any delegation to COP30 in November — the first US absence from a UN climate summit since talks began in 1993 — and exited the Paris Climate Accord for a second time after President Donald Trump, who denies climate change, returned to office. “The president has been clear that the United States will not participate in the bogus climate agenda,” Taylor Rogers, a White House spokeswoman, said in a statement to the New York Times. Green momentum Delegates from the 24 founding nations of the fossil fuel phase-out conference initiative celebrate at COP30 in Belém, Brazil. As the US-Israeli war on Iran enters its third month with no clear end in sight, its shockwaves have caused the largest energy crisis in history – one that International Energy Agency chief Fatih Birol recently described as “worse than those of 1973, 1979, and 2022 combined.” It is the second major war-driven oil price shock in less than five years, after Russia’s invasion of Ukraine, and the crisis third since COVID-19 shut the global economy in 2019. That cascade of global crises is reshaping how COP negotiators are approaching this year’s summit. “No one has said this crisis is a reminder that we need to be more reliant on fossil fuels,” said Chris Bowen, Australia’s climate minister and lead negotiator for COP31, in his first interview in the role with the Guardian. “There’s a real appetite to emphasise reliability and energy sovereignty this year, and I think that does open up more opportunities for COP31.” The new war makes Colombia’s conference notably prescient, demonstrating the stability renewables could offer energy systems insulated from oil shocks. Wind gusts and sun rays – unlike roughly 20% of the world’s oil, gas and fertilizer – cannot be blocked in the Strait of Hormuz. “Sunlight travels 93 million miles to reach the earth,” environmentalist Bill McKibben wrote in a recent analysis. “None of them through the Strait of Hormuz.” Green momentum is visible around the world. Amid the Iran war, China smashed its previous solar technology export record by 50% in March, with the largest growth in Asian and African countries most reliant on Middle East fossil fuels, according to the energy think tank Ember. Last year, electricity from low-carbon sources overtook coal for the first time, and solar power generation rose 33% in 2025 as fossil fuel generation remained flat, Ember found. “Fossil shocks are boosting the solar surge,” said Euan Graham, a lead analyst for the Ember report. “Solar has already become the engine of the global economy, and now the current fossil fuel price shocks are taking it up a gear.” Some analysts have suggested developing nations may turn to home-produced coal to offset the shock, but solar is simply more competitive on cost and growth in the long- and short-term, Birol said. “COPs are unlikely now to be Paris or Copenhagen — outstanding successes or heartbreaking failures,” Bowen added. “COPs are more likely to be incremental progress. The question is how big that progress is.” Fossil fuel superpowers reap billions from crisis Russian oil companies are on course to make over $23 billion in additional profits this year due to the oil crisis, replenishing Putin’s wartime coffers as his invasion of Ukraine presses on. Yet even as renewables surge, windfall profits from the oil crisis continue to flow into the coffers of nations pivotal to blocking UN climate agreements. Russia, the United States and Saudi Arabia stand to gain the most: billions in new funding for Vladimir Putin’s war chest amid a grinding war in Ukraine, $60 billion in projected windfall profits for US oil and gas, and soaring values for state-owned oil giant Saudi Aramco despite major damage to its infrastructure in the war. A climate-forward shift from this axis of obstruction at COP31 — its strategy now vindicated by the crisis — is unlikely. The world’s top 100 oil and gas companies have earned an additional $30 million in profits per hour since the Iran war began. The oil and gas industry has made around $1 trillion in annual profits for over five decades, making it history’s most profitable industry. The same constellation of fossil fuel nations derailed hopes for a legally binding plastics treaty in August. With energy demand for fossil fuels falling, the industry is increasingly rerouting oil and gas into plastic and petrochemicals, making production limits in any treaty an existential threat. As coffers at ExxonMobil, Saudi Aramco and Rosneft fill, the World Food Programme estimates 45 million people will be pushed into hunger as a result of the oil and fertilizer crisis, with the toll potentially rising to record levels. Out of the ashes of Bélem: a coalition of the willing? As leaders gather at #SantaMarta conference on Transitioning Away from Fossil Fuels, fossil fuel giants are set to make nearly $3,000 every second in 2026—$94B that could power 50M people in Africa with solar. This isn’t normal, and it’s certainly not fair.#MakeRichPollutersPay pic.twitter.com/3U7k6onGUl — Oxfam in Africa (@OxfaminAfrica) April 27, 2026 Colombia launched the initiative in the final hours of COP30 in Belém, Brazil, when standoffs between countries supporting more ambition, and those blocking it, sent the summit into freefall. Two weeks of intensive negotiations ended in no concrete financial or legal outcomes from the much-hyped meeting in the Amazon – whose gradual is an iconic symbol of climate change. The frustration from that collapse spurred Colombia to launch the last-minute call for a fossil fuel phase-out conference, which at the time drew just 24 signatures from the 200 nations present. With 54 countries attending this week, the shape of Colombia’s initiative recalls a similar coalition that took years to build during negotiations for a legally binding plastic pollution treaty. That alliance, the High Ambition Coalition, had 20 founding members when talks opened in Paris in 2022. By the final round in Geneva in August, its then 75 members had rallied some 120 nations behind core binding provisions, including phasing out harmful chemicals from plastic production. That treaty ultimately fell short — blocked by the same axis of obstruction, this time led by Saudi Arabia and flanked by the US, Russia and Iran — but the negotiations produced real movement in global cooperation and national policymaking. Campaigners are aiming for the the same arc of momentum to be played in the fossil fuels arena now but more successfully. The big prize would be a treaty modelled on what the plastics coalition tried, but failed, to build, this time aimed at production limits on oil, gas and coal. “Santa Marta must support a coalition of the doers to recognise and remove legal barriers to halt oil and gas expansion — particularly offshore — and to pursue effective international cooperation on fossil fuel phase-out, through the future negotiation of a Fossil Fuel Treaty,” Reisch said. “Phasing out fossil fuels is not just a scientific necessity and a legal obligation, it’s also a critical opportunity to break free from a destructive system.” Image Credits: Ben Wicks, Yves Alarie. Developed Countries Propose ‘Hybrid’ Model Ahead of Pandemic Agreement Talks 26/04/2026 Kerry Cullinan IGWG negotiators (clockwise from top L): Nurhafiza Hamza (Malaysia), moderator Guilherme Faviero (AIDS Health Foundation), Jean Karydakis (Brazil), Taime Sylvester (Namibia), Eirik Rodseth Bakka (Norway) and Adeel Mumtaz Khokhar (Pakistan). Yet another negotiating session on the outstanding annex of the Pandemic Agreement begins at the World Health Organization’s (WHO) headquarters on Monday (27 April) – and developed nations have presented a “hybrid” solution in an attempt to find consensus. The “hybrid” proposal consists of a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. Adeel Mumtaz Khokhar, First Secretary to the Permanent Mission of Pakistan in Geneva, confirmed that a “hybrid” proposal had been presented to developing countries by some developed countries, but declined to name them. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The outstanding annex will set out terms for a pathogen access and benefit-sharing (PABS) system that ensures all countries have access to countermeasures to combat a pandemic or public health emergency of international concern (PHEIC) – unlike during COVID-19 when rich countries hoarded scarce vaccines. “We have been hearing rumours about this hybrid system for the past two IGWG [Intergovernmental Working Group] meetings, and finally, some developed country negotiator took pity on us and presented it,” Khokhar told a high-level webinar hosted by the University of Miami’s Public Health Policy Lab and AIDS Healthcare Foundation (AHF) last week. The proposal envisages two categories for biological material, Khokhar explained. To access one category, countries and manufacturers will “have to follow certain terms and conditions”, and these will be included in the PABS system. No terms or conditions apply to the other category of material, including benefit-sharing obligations. However, Third World Network (TWN), a civil society alliance tracking the negotiations, says that the hybrid system proposed by developed countries also envisages a split between information sharing and benefits. “Developed countries expect developing countries to share pathogen samples and sequence information freely, while deferring benefit-sharing to future negotiations between WHO and pharmaceutical manufacturers,” writes TWN in a recent brief. Maintains the status quo For Khokhar, the hybrid proposal “is essentially the status quo” as it allows parties to “share the way they want to share”. “So I’m not sure how fundamentally the needle is moved by this proposal. All I can understand from this proposal is that they want to retain and preserve the status quo, which, from a developing country negotiations perspective, is a disappointment.” Nurhafiza Hamza, Minister Counsellor for Health at Malaysia’s Permanent Mission to Geneva, explained that developing countries want “a set of mandatory benefit-sharing that is acceptable to different categories of users of the PABS system” – member states and pharmaceutical companies – during health emergencies. “If manufacturers have VTDs during a PHEIC or pandemic emergency, they should share,” said Hamza. “It is important to get some mandatory benefit sharing and not a menu of options, where manufacturers can pick and choose.” Kicking the can down the road? France’s Ambassador Anne-Claire Amprou, co-chair of the talks, and WHO Director-General Dr Tedros at the conclusion of the Pandemic Agreement talks. Jean Karydakis, Counsellor in Brazil’s Mission in Geneva, acknowledged that the positions of the different groups – primarily developed countries versus developing countries – are fairly entrenched. “We won’t change other countries’ positions at this time,” he acknowledged. “The question now is whether we can find possible creative language, also bearing in mind that we will have a Conference of the Parties (COP) later on that will need to revisit and detail further what we cannot agree right now.” Karydakis also asserted that “90% of of the text is already agreed in the Pandemic Agreement, and the Pandemic Agreement was already adopted. “ But the PABS system was a contentious issue that evaded negotiators, who packaged it into an annex and kicked it down the road to new negotiations. This enabled the World Health Assembly to adopt the Pandemic Agreement last year, described by some observers as the Pandemic Agreement Lite precisely because it dodged the detail about PABS. Adopting a vague PABS annex and kicking further details down the road again – this time to the COP – might save face for multilateralism. But it simply delays the adoption of the Pandemic Agreement to yet another set of talks, leaving all member states vulnerable to public health emergencies in the meantime. Standard contracts? Developing countries want the annex to include a standard contract to govern access to biological material and digital sequencing, including benefit-sharing obligations. But Khokhar said that the IGWG Bureau and “other colleagues” have expressed that “a full standardised contract may not be the appropriate way”, as it is hard to predict what – if any – VTDs may be developed as a result. “Fair enough,” he said, adding that developing countries are prepared to explore the inclusion of a “basic contract” followed by a PABS contract, if a party has developed a medical countermeasure. “But what is their answer to this suggestion? Let’s have an open and a closed system. So, in this endeavour to try and find and create a multilateral system, we are actually going back to our national systems… What new system are we creating here? We’re creating nothing new?” For TWN, the lack of “contractually enforceable legal obligations for recipients of PABS materials and sequence information “will add to the legal uncertainty, as benefit-sharing will depend on the WHO concluding contracts with manufacturers. Namibian negotiator Taime Sylvester said that the funders of research in developing countries are “overwhelmingly high-income country governments and foundations”. They could “include PABS compliance as a condition of their grants,” said Sylvester, pointing to the example of the European Union’s Horizon Europe (2021–2027), its funding programme for research and innovation. This requires researchers to commit to Nagoya Protocol compliance, which mandates fair benefit-sharing from the use of genetic resources. Prospects for agreement Norwegian Health Counsellor Eirik Rodseth Bakka acknowledged that there are “significant outstanding issues, and I think as a collective, we do need to see significant progress next week”. However, he stressed that member states have the opportunity to “correct some of those inequities from the COVID-19 pandemic,” especially early access to vaccines for low- countries and lower-middle-income countries, and enabling “to the extent possible that there is more technology transfer and access to access to manufacturing capacity.” Karydakis expressed hope that “we will get this by May”, adding that talks may need to continue alongside the World Health Assembly in late May, the deadline for the annex. He also joked that night sessions were necessary to get people tired and hungry and “only able to leave the room when the deal is reached.” Sylvester said that Namibia believes that “a fair, functional, legally grounded PABS system” is possible and will assist both the global south and the global north need this functional system to succeed. So we we believe it. We believe that it can happen which is above and beyond, or we’re not asking any country to stand to a higher standard. We’re asking the same standards. Malaysia’s Hamza described the PABS system as “the litmus test for equity”. “We will have to see whether states will come in next week and design a PABS system that would actually make an improvement in the current status quo.When the Group for Equity gets together, the first thing we will assess is whether what we have agreed on, each paragraph, is really delivering equity.” Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Ghana Rebuffs US Health Deal – But South Africa and Zambia Struggle Without Aid 29/04/2026 Kerry Cullinan US Ambassador to the UN Mike Waltz (left) at the launch of the ‘Trade over Aid’ event at the New York Stock Exchange this week. Ghana has become the latest African country to reject the United States’ terms for bilateral health assistance, particularly the requirement to share sensitive health data, according to Reuters. Late last year, Zimbabwe rejected US terms for health assistance, particularly the demand to share pathogen data without any “corresponding guarantee of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data,” according to government spokesperson Nick Mangwana. Zambia has until 30 April to decide on whether to avail its minerals – primarily copper, cobalt and lithium – to US companies in exchange for health assistance. US aid supported antiretroviral treatment for an estimated 1,3 million Zambians. In the wake of disruptions since President Donald Trump assumed office last January, some Zambian hospitals are seeing an increase in AIDS cases, according to the New York Times. Back in December, the US announced Zambia had committed to a plan to unlock “a substantial grant package of US support in exchange for collaboration in the mining sector and clear business sector reforms that will drive economic growth and commercial investment that benefits both the United States and Zambia”. But this has never materialised amid renewed US pressure on Zambia to open its mineral wealth to the US. Meanwhile, South Africa has been frozen out of health aid by the Trump administration – in the main, for charging Israel with genocide at the International Criminal Court and for policies aimed at addressing apartheid-era discrimination that the US claims are anti-white. The loss of US funding has “damaged critical health services, dismantled HIV prevention programs, and disrupted world-class South Africa-U.S. research collaboration,” according to a report published last week by Physicians for Human Rights (PHR), Advocates for the Prevention of HIV in South Africa (APHA), and Emthonjeni Counselling and Training. ‘Trade over aid’ The terms of the Memorandums of Understanding (MOU) that the US is seeking with key countries, as part of its “America First Global Health Strategy” (AFGHSD), are overwhelmingly transactional. This week, the US entrenched this approach at the launch of its ‘Trade over Aid’ initiative at the New York Stock Exchange, asserting that the free market is the “surest route to economic prosperity” Ghana is Africa’s largest gold producer. It is unclear whether the US tried to use its aid offer to extract minerals, as it has in other countries. However, this is unlikely to have gone down well as Ghana is clamping down on foreign mining operations. In the past few weeks, the country’s Minerals Commission has given three international firms until the end of the year to transfer their gold mining operations to locals. Ghanaian President John Mahama is also championing the “Accra Reset”, launched last year to encourage African countries to invest more of their domestic budgets in their health and depend less on aid. At the same time, Ghana is heavily indebted and recently held off paying newly recruited nurses as it lacked the finances. US role in DRC conflict? President Donald Trump meets with DRC President Felix Tshisekedi and President Paul Kagame of the Republic of Rwanda, in the Oval Office in December 2025. The US held off signing an MOU with the DRC on 5 December, when it signed deals with Rwanda and Kenya on the sidelines of a peace accord between the DRC and Rwanda, allegedly the sponsor of the M23 rebels waging war inside the DRC. Instead, the US and DRC first signed a “strategic partnership agreement” to “promote secure, reliable, and mutually beneficial critical mineral flows for commercial and defense purposes”, according to the US State Department. The health MOU followed on 26 February. The DRC is one of the world’s most important sources of rare earth minerals, but China has dominated the purchasing and processing of its minerals. Following the agreement, the DRC offered US investors stakes in state-owned mineral assets. In late March, a US company, Virtus, bought a cobalt mine. Recently, it emerged that the DRC has offered mining opportunities to US companies in Rubaya, currently held by M23 rebels, indicating that the US would need to play a role in maintaining peace if it wants access to rare minerals. This week, the DRC announced the formation of a $100 million initiative to establish “mining guards” to secure mines, with investment from the US and the United Arab Emirates. However, lawyers in the DRC have challenged the MOU in court, while part of Kenya’s MOU has been suspended by a High Court in the face of an ongoing court challenge. South Africa in the cold South African HIV scientist Prof Linda-Gail Bekker received a standing ovation at the International AIDS Conference in 2022 when she announced the results of the lenacapavir clinical trial. South Africa has the biggest HIV population in the world, and was the largest international recipient of US National Institutes of Health (NIH) research funds, as well as getting funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR). “Our report illustrates what an ‘America First’ approach to global health looks like: Lifesaving programs shuttered, world-class research jettisoned, decades of progress against HIV/AIDS jeopardized. All to the harm of, not only South Africans, but to Americans and the global public as well,” said Thomas McHale, director of public health at PHR and a report co-author. Co-author Emily Bass warned: “Short-sighted, sudden withdrawal of funds for critical components of the HIV response will cause long-term harm to infants, children, adolescent girls and young women, and other groups at the highest risk of HIV.” The report mentions two scientific breakthroughs that came from US-South African research partnerships, namely the clinical trial of lenacapavir, an injectable pre-exposure prophylaxis (PrEP) that is almost 100% effective in preventing HIV, and updated global guidelines for treating drug-resistant tuberculosis (TB). These breakthroughs “directly benefit Americans”, the authors argue. “By freezing research funding to South Africa, the Trump administration is sabotaging the United States’ own future health and national security.” The report is based on interviews with South African doctors, researchers, people living with HIV, and others involved in South Africa’s HIV response efforts. Image Credits: Daniel Torok/ White House , Kerry Cullinan. Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Making Better Vaccine Choices in a Shifting Global Health Landscape 27/04/2026 Charlie Weller A baby gets a first dose of the measles, mumps and rubella (MMR) vaccine at a health center in Côte d’Ivoire. Global aid cuts have left countries struggling to meet childhood vaccine schedules. In an era of big global health budget cuts that often demand tough choices, identifying vaccine needs and priorities at national level is increasingly important. As we observe World Immunization Week, it’s time to recognize the pivotal role that National Immunization Technical Advisory Groups (NITAGs) can play in guiding effective, evidence-based decisions – alongside global guidance from the World Health Organization. From infancy to old age, vaccines are a life-saving tool. Over the past 50 years, vaccines have saved more than 150 million lives. They play a decisive role in keeping us safe from diseases through childhood, strengthening our immune responses in adulthood, and keeping us out of hospital in our older years. Immunisation currently prevents 3.5 million to 5 million deaths every year from diseases like tetanus, pertussis, influenza, and measles. Without vaccines, diseases consigned to the past could resurge in our present. Funding cuts and reduced resources are increasing barriers to vaccine research and development, as well as equitable access to immunisation – including the routine vaccination of young children in low- and middle-income countries. This reduction in support and resources is forcing organisations like the World Health Organization and Gavi, the Vaccine Alliance, to rethink how they operate. Vaccine decision-making is no longer about access alone; it’s about prioritisation under constraints. (Left to right columns). Deaths averted, years of life saved, and years of full health gained due to vaccination. From global guidance to national decision-making Many countries still rely heavily on vaccine recommendations made by the WHO through the Strategic Advisory Group of Experts on Immunization (SAGE). While being scientifically robust and relevant they do not always reflect the specific needs, challenges or health systems of individual countries. With global health funding undergoing dramatic reductions, countries and regions most affected by infectious diseases are facing difficult decisions about which diseases to prioritise and how best to procure and roll-out vaccines to maintain even fuller vaccination schedules. This greater emphasis on country-level decision-making is appropriate – countries affected by diseases are best placed to make decisions on how to tackle them. However, it takes time to build expertise and evidence, and responsibility is being decentralised faster than this capacity can be developed, with experts required to wear multiple hats. This is not merely a technical challenge, but a political and operational one. It requires a reshaping of power and accountability in global health structures. filling gaps in infrastructure to support more national and regional decision-making. SAGE Executive Secretary Joachim Hombach presents updates on WHO vaccine recommendations at a 2025 briefing. While such global guidance remains critical, a greater emphasis on country-level decision-making is also appropriate. Regional decisions need regional expertise Building regional sharing of expertise is now as critical as supply chains. This is where advisory groups such as the National Immunization Technical Advisory Groups (NITAGs), can play a pivotal role in guiding effective, evidence-based decisions. Each country’s NITAGs expertise differs, but their aim is the same – multidisciplinary independent experts assess whether international knowledge is applicable and relevant to local contexts, informing appropriate policy recommendations at a national level and bridging the gap between research and policy action. The impact of NITAGs can be felt quickly, allowing the introduction of specific vaccines that better suit the regional needs – whether it’s switching from one malaria vaccine to another in Nigeria, or the introduction of a Hepatitis B vaccine given at birth in Lesotho. For this model to work effectively, sustained funding is needed not just for research projects but to support policy-relevant expertise, enabling research to be translated into country-relevant recommendations. This is why Wellcome is investing in the African-led NITAG Support Hub, or NISH, which helps strengthen NITAGs across Africa. Through local evidence and support, and by sharing expertise and best practice via resource hubs, countries can be better prepared to navigate choices, including which of the increasingly robust array of lifesaving vaccines to prioritise, where, and how – all whilst aid and global health budgets are shrinking. Similarly, Gavi, The Vaccine Alliance has introduced ‘The Gavi Leap’ – a new operating model aiming to support country self-reliance to transition away from donor-led systems. Gavi Leap is increasing resources to help countries decide their own priorities, financing and delivery of vaccines with the long-term goal of immunisation sustainability. The intervention trade-offs A Kinshasa neighbourhood water point in DR Congo. Better WASH practices can complement cholera vaccination efforts in fighting the deadly disease. Amidst global instability, decision-makers increasingly need to balance the benefits of investing in one vaccine over another, as well as balancing the costs of vaccine procurement and distribution with spending on other interventions such as diagnostics and therapeutics, surveillance and health system strengthening. For example, while oral cholera vaccines alone protect individuals against the disease, and water, sanitation and hygiene (WASH) alone reduces the amount of bacteria in the environment, studies suggest that combining the oral cholera vaccine with improved household WASH leads to optimal protection. Oral cholera vaccination campaign in Democratic Republic of Congo, December 2023. There is a tricky balance to strike, taking into account factors such as available resources; behavioural attitudes to interventions; the benefits and risks of mass immunisation campaigns; and the needs of vulnerable, under-resourced communities. And any public health policies must take a long-term view, with the ability to adapt to changing circumstances – such as the emergence of new outbreaks, new pathogen variants, and new forms of disease resistance. Diverse expertise combined with awareness of local needs and barriers is essential to ensure vaccines are neither over-prioritised nor underused. Global health will, and must, be a global effort, and international guidance remains essential. But it cannot replace regional and national judgement and local knowledge of community needs and challenges. Investment in expertise means equitable vaccine policies With tightening global funding, choices between vaccines and other essential health interventions are unavoidable. Doing so without investment in more localised expertise is not. Investing in national and regional advisory capacity, knowledge-sharing and long-lasting expertise is not a luxury, it is the foundation of smarter, fairer vaccine decisions in an increasingly constrained world. Charlie Weller is the Head of Prevention in Wellcome’s Infectious Disease team. Since 2016, she has led the team to develop new and improved vaccines and antibodies – from managing the research and funding response to the Ebola epidemic of 2014-2015, to helping the co-founding of the Coalition for Epidemic Preparedness Innovations (CEPI), which is investing in new vaccine development that protects the world from epidemic and pandemic threats. Image Credits: UNICEF, Shattock A, Johnson H, Sim S et al.,The Lancet, May 2024, E. Fletcher/Health Policy Watch , Eduardo Soteras Jalil/ WHO, Esther Nsapu/Wellcome Trust. UN Deadlock and Iran War Oil Shocks Push 54 Nations to Chart Fossil Fuel Phase Out 27/04/2026 Stefan Anderson Governments, civil society and indigenous communities gather in Santa Marta Colombia to address the hurdle decades of UN climate summits have failed to clear: phasing out fossil fuels. More than 50 countries are gathering this week on Colombia’s Caribbean coast to launch a coalition for phasing out fossil fuels, as a third month of war in Iran exposes the costs of a global economy run on the oil, gas and coal driving the climate crisis that decades of deadlocked UN climate talks have failed to curb. No outcome text, funding or binding legal commitments are expected to come out of Santa Marta. Yet that the meeting exists at all – and is attended by several major fossil fuel powers including Australia, Canada, the United Kingdom, Nigeria and Norway – is a source of optimism for observers hoping it may be the start of a wind change in climate politics. The final tally of 54 states attending the first-of-its-kind conference is more than double the number of founding signatories who joined Colombia’s initiative as UN climate talks collapsed at COP30 in Belém last November. Combined, the coalition in Santa Marta represents around half of global GDP and 2.5 billion people, roughly a third of the global population. “The task for those attending is clear: not to debate whether to phase out fossil fuels but to determine how to do it – rapidly, fairly, and in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. “It has never been more urgent to leave behind oil, gas and coal than it is today.” Climate Change Is Here, And It’s Killing Millions Ministers and high-level delegations arrive on Tuesday and will negotiate through Wednesday evening. The primary goal, its host Colombia said, is “to launch an international coalition to jointly implement the transition away from fossil fuels.” “We need a multilateralism that is more deeply rooted in the people and not just in governments, biases or economic lobbying,” Colombian environment minister Irene Velez-Torres told AFP. “We need new alignments, new alliances. In that sense, we are a new power today,” she said, pointing to the global coalition in attendance. Fossil fuels are also driving a mounting public health catastrophe. Heat exposure now claims an estimated 546,000 lives annually, while air pollution from burning oil, gas and coal kills another 2.5 million people each year, according to the Lancet Countdown on health and climate change. “Fossil fuels are causing immediate harm,” said Jeni Miller, executive director of the Global Climate and Health Alliance, a consortium of more than 250 health organisations that submitted recommendations to the conference. “Phasing them out is not only about protecting the planet but also about saving lives in the near term, reducing strain on health systems, and creating greener, more just, and healthier societies.” The talks will aim to allow space for constructive negotiations among like-minded nations, unencumbered by the consensus-based UN system. Agreements at COPs require all 200 nations to sign off on the final text, a system which has allowed petrostates to block progress for decades. “The consensus methodology has resulted in a de facto veto against countries like Colombia that want more ambitious discussions on decisions, particularly related to fossil fuels,” Velez-Torres said. Who’s at the party? Boats sit along the Caribbean coastline of Santa Marta, Colombia, host city of the conference. Participants in Santa Marta include the European Union, the United Kingdom, small island developing states on the frontlines of sea level rise, several dozen developing nations, and COP31 co-hosts Turkey and Australia. Organisers said more than 2,600 civil society and indigenous community representatives are also in attendance in-person and online. Fossil fuel superpowers in the Gulf, the United States and Russia are not present. The world’s other biggest emitters including China, India, Iran and Japan, will also be absent. But unlike UN proceedings, which invite all member states by default, the tone struck by Colombia and the Netherlands is different: if you’re not going to help, don’t come. “We are not going to have boycotters or climate denialists at the table,” Vélez-Torres told the Guardian. “Whatever nations have not yet taken that decision, then this is not the space for them.” “Despite our differences, all participants agree on the need to prioritise science and to move forward, urgently and in a coordinated manner, toward phasing out the production and consumption of natural gas, coal, and oil,” she added in a statement shared by the summit presidency. The United States, for example, was not even invited. The Trump administration declined to send any delegation to COP30 in November — the first US absence from a UN climate summit since talks began in 1993 — and exited the Paris Climate Accord for a second time after President Donald Trump, who denies climate change, returned to office. “The president has been clear that the United States will not participate in the bogus climate agenda,” Taylor Rogers, a White House spokeswoman, said in a statement to the New York Times. Green momentum Delegates from the 24 founding nations of the fossil fuel phase-out conference initiative celebrate at COP30 in Belém, Brazil. As the US-Israeli war on Iran enters its third month with no clear end in sight, its shockwaves have caused the largest energy crisis in history – one that International Energy Agency chief Fatih Birol recently described as “worse than those of 1973, 1979, and 2022 combined.” It is the second major war-driven oil price shock in less than five years, after Russia’s invasion of Ukraine, and the crisis third since COVID-19 shut the global economy in 2019. That cascade of global crises is reshaping how COP negotiators are approaching this year’s summit. “No one has said this crisis is a reminder that we need to be more reliant on fossil fuels,” said Chris Bowen, Australia’s climate minister and lead negotiator for COP31, in his first interview in the role with the Guardian. “There’s a real appetite to emphasise reliability and energy sovereignty this year, and I think that does open up more opportunities for COP31.” The new war makes Colombia’s conference notably prescient, demonstrating the stability renewables could offer energy systems insulated from oil shocks. Wind gusts and sun rays – unlike roughly 20% of the world’s oil, gas and fertilizer – cannot be blocked in the Strait of Hormuz. “Sunlight travels 93 million miles to reach the earth,” environmentalist Bill McKibben wrote in a recent analysis. “None of them through the Strait of Hormuz.” Green momentum is visible around the world. Amid the Iran war, China smashed its previous solar technology export record by 50% in March, with the largest growth in Asian and African countries most reliant on Middle East fossil fuels, according to the energy think tank Ember. Last year, electricity from low-carbon sources overtook coal for the first time, and solar power generation rose 33% in 2025 as fossil fuel generation remained flat, Ember found. “Fossil shocks are boosting the solar surge,” said Euan Graham, a lead analyst for the Ember report. “Solar has already become the engine of the global economy, and now the current fossil fuel price shocks are taking it up a gear.” Some analysts have suggested developing nations may turn to home-produced coal to offset the shock, but solar is simply more competitive on cost and growth in the long- and short-term, Birol said. “COPs are unlikely now to be Paris or Copenhagen — outstanding successes or heartbreaking failures,” Bowen added. “COPs are more likely to be incremental progress. The question is how big that progress is.” Fossil fuel superpowers reap billions from crisis Russian oil companies are on course to make over $23 billion in additional profits this year due to the oil crisis, replenishing Putin’s wartime coffers as his invasion of Ukraine presses on. Yet even as renewables surge, windfall profits from the oil crisis continue to flow into the coffers of nations pivotal to blocking UN climate agreements. Russia, the United States and Saudi Arabia stand to gain the most: billions in new funding for Vladimir Putin’s war chest amid a grinding war in Ukraine, $60 billion in projected windfall profits for US oil and gas, and soaring values for state-owned oil giant Saudi Aramco despite major damage to its infrastructure in the war. A climate-forward shift from this axis of obstruction at COP31 — its strategy now vindicated by the crisis — is unlikely. The world’s top 100 oil and gas companies have earned an additional $30 million in profits per hour since the Iran war began. The oil and gas industry has made around $1 trillion in annual profits for over five decades, making it history’s most profitable industry. The same constellation of fossil fuel nations derailed hopes for a legally binding plastics treaty in August. With energy demand for fossil fuels falling, the industry is increasingly rerouting oil and gas into plastic and petrochemicals, making production limits in any treaty an existential threat. As coffers at ExxonMobil, Saudi Aramco and Rosneft fill, the World Food Programme estimates 45 million people will be pushed into hunger as a result of the oil and fertilizer crisis, with the toll potentially rising to record levels. Out of the ashes of Bélem: a coalition of the willing? As leaders gather at #SantaMarta conference on Transitioning Away from Fossil Fuels, fossil fuel giants are set to make nearly $3,000 every second in 2026—$94B that could power 50M people in Africa with solar. This isn’t normal, and it’s certainly not fair.#MakeRichPollutersPay pic.twitter.com/3U7k6onGUl — Oxfam in Africa (@OxfaminAfrica) April 27, 2026 Colombia launched the initiative in the final hours of COP30 in Belém, Brazil, when standoffs between countries supporting more ambition, and those blocking it, sent the summit into freefall. Two weeks of intensive negotiations ended in no concrete financial or legal outcomes from the much-hyped meeting in the Amazon – whose gradual is an iconic symbol of climate change. The frustration from that collapse spurred Colombia to launch the last-minute call for a fossil fuel phase-out conference, which at the time drew just 24 signatures from the 200 nations present. With 54 countries attending this week, the shape of Colombia’s initiative recalls a similar coalition that took years to build during negotiations for a legally binding plastic pollution treaty. That alliance, the High Ambition Coalition, had 20 founding members when talks opened in Paris in 2022. By the final round in Geneva in August, its then 75 members had rallied some 120 nations behind core binding provisions, including phasing out harmful chemicals from plastic production. That treaty ultimately fell short — blocked by the same axis of obstruction, this time led by Saudi Arabia and flanked by the US, Russia and Iran — but the negotiations produced real movement in global cooperation and national policymaking. Campaigners are aiming for the the same arc of momentum to be played in the fossil fuels arena now but more successfully. The big prize would be a treaty modelled on what the plastics coalition tried, but failed, to build, this time aimed at production limits on oil, gas and coal. “Santa Marta must support a coalition of the doers to recognise and remove legal barriers to halt oil and gas expansion — particularly offshore — and to pursue effective international cooperation on fossil fuel phase-out, through the future negotiation of a Fossil Fuel Treaty,” Reisch said. “Phasing out fossil fuels is not just a scientific necessity and a legal obligation, it’s also a critical opportunity to break free from a destructive system.” Image Credits: Ben Wicks, Yves Alarie. Developed Countries Propose ‘Hybrid’ Model Ahead of Pandemic Agreement Talks 26/04/2026 Kerry Cullinan IGWG negotiators (clockwise from top L): Nurhafiza Hamza (Malaysia), moderator Guilherme Faviero (AIDS Health Foundation), Jean Karydakis (Brazil), Taime Sylvester (Namibia), Eirik Rodseth Bakka (Norway) and Adeel Mumtaz Khokhar (Pakistan). Yet another negotiating session on the outstanding annex of the Pandemic Agreement begins at the World Health Organization’s (WHO) headquarters on Monday (27 April) – and developed nations have presented a “hybrid” solution in an attempt to find consensus. The “hybrid” proposal consists of a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. Adeel Mumtaz Khokhar, First Secretary to the Permanent Mission of Pakistan in Geneva, confirmed that a “hybrid” proposal had been presented to developing countries by some developed countries, but declined to name them. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The outstanding annex will set out terms for a pathogen access and benefit-sharing (PABS) system that ensures all countries have access to countermeasures to combat a pandemic or public health emergency of international concern (PHEIC) – unlike during COVID-19 when rich countries hoarded scarce vaccines. “We have been hearing rumours about this hybrid system for the past two IGWG [Intergovernmental Working Group] meetings, and finally, some developed country negotiator took pity on us and presented it,” Khokhar told a high-level webinar hosted by the University of Miami’s Public Health Policy Lab and AIDS Healthcare Foundation (AHF) last week. The proposal envisages two categories for biological material, Khokhar explained. To access one category, countries and manufacturers will “have to follow certain terms and conditions”, and these will be included in the PABS system. No terms or conditions apply to the other category of material, including benefit-sharing obligations. However, Third World Network (TWN), a civil society alliance tracking the negotiations, says that the hybrid system proposed by developed countries also envisages a split between information sharing and benefits. “Developed countries expect developing countries to share pathogen samples and sequence information freely, while deferring benefit-sharing to future negotiations between WHO and pharmaceutical manufacturers,” writes TWN in a recent brief. Maintains the status quo For Khokhar, the hybrid proposal “is essentially the status quo” as it allows parties to “share the way they want to share”. “So I’m not sure how fundamentally the needle is moved by this proposal. All I can understand from this proposal is that they want to retain and preserve the status quo, which, from a developing country negotiations perspective, is a disappointment.” Nurhafiza Hamza, Minister Counsellor for Health at Malaysia’s Permanent Mission to Geneva, explained that developing countries want “a set of mandatory benefit-sharing that is acceptable to different categories of users of the PABS system” – member states and pharmaceutical companies – during health emergencies. “If manufacturers have VTDs during a PHEIC or pandemic emergency, they should share,” said Hamza. “It is important to get some mandatory benefit sharing and not a menu of options, where manufacturers can pick and choose.” Kicking the can down the road? France’s Ambassador Anne-Claire Amprou, co-chair of the talks, and WHO Director-General Dr Tedros at the conclusion of the Pandemic Agreement talks. Jean Karydakis, Counsellor in Brazil’s Mission in Geneva, acknowledged that the positions of the different groups – primarily developed countries versus developing countries – are fairly entrenched. “We won’t change other countries’ positions at this time,” he acknowledged. “The question now is whether we can find possible creative language, also bearing in mind that we will have a Conference of the Parties (COP) later on that will need to revisit and detail further what we cannot agree right now.” Karydakis also asserted that “90% of of the text is already agreed in the Pandemic Agreement, and the Pandemic Agreement was already adopted. “ But the PABS system was a contentious issue that evaded negotiators, who packaged it into an annex and kicked it down the road to new negotiations. This enabled the World Health Assembly to adopt the Pandemic Agreement last year, described by some observers as the Pandemic Agreement Lite precisely because it dodged the detail about PABS. Adopting a vague PABS annex and kicking further details down the road again – this time to the COP – might save face for multilateralism. But it simply delays the adoption of the Pandemic Agreement to yet another set of talks, leaving all member states vulnerable to public health emergencies in the meantime. Standard contracts? Developing countries want the annex to include a standard contract to govern access to biological material and digital sequencing, including benefit-sharing obligations. But Khokhar said that the IGWG Bureau and “other colleagues” have expressed that “a full standardised contract may not be the appropriate way”, as it is hard to predict what – if any – VTDs may be developed as a result. “Fair enough,” he said, adding that developing countries are prepared to explore the inclusion of a “basic contract” followed by a PABS contract, if a party has developed a medical countermeasure. “But what is their answer to this suggestion? Let’s have an open and a closed system. So, in this endeavour to try and find and create a multilateral system, we are actually going back to our national systems… What new system are we creating here? We’re creating nothing new?” For TWN, the lack of “contractually enforceable legal obligations for recipients of PABS materials and sequence information “will add to the legal uncertainty, as benefit-sharing will depend on the WHO concluding contracts with manufacturers. Namibian negotiator Taime Sylvester said that the funders of research in developing countries are “overwhelmingly high-income country governments and foundations”. They could “include PABS compliance as a condition of their grants,” said Sylvester, pointing to the example of the European Union’s Horizon Europe (2021–2027), its funding programme for research and innovation. This requires researchers to commit to Nagoya Protocol compliance, which mandates fair benefit-sharing from the use of genetic resources. Prospects for agreement Norwegian Health Counsellor Eirik Rodseth Bakka acknowledged that there are “significant outstanding issues, and I think as a collective, we do need to see significant progress next week”. However, he stressed that member states have the opportunity to “correct some of those inequities from the COVID-19 pandemic,” especially early access to vaccines for low- countries and lower-middle-income countries, and enabling “to the extent possible that there is more technology transfer and access to access to manufacturing capacity.” Karydakis expressed hope that “we will get this by May”, adding that talks may need to continue alongside the World Health Assembly in late May, the deadline for the annex. He also joked that night sessions were necessary to get people tired and hungry and “only able to leave the room when the deal is reached.” Sylvester said that Namibia believes that “a fair, functional, legally grounded PABS system” is possible and will assist both the global south and the global north need this functional system to succeed. So we we believe it. We believe that it can happen which is above and beyond, or we’re not asking any country to stand to a higher standard. We’re asking the same standards. Malaysia’s Hamza described the PABS system as “the litmus test for equity”. “We will have to see whether states will come in next week and design a PABS system that would actually make an improvement in the current status quo.When the Group for Equity gets together, the first thing we will assess is whether what we have agreed on, each paragraph, is really delivering equity.” Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Record European Heatwaves Shrink Glaciers and Diminish Snow Cover in 2025 29/04/2026 Disha Shetty Europe experienced record extremes in 2025, according to WMO’s latest assessment. Around 95% of Europe experienced above-average temperatures in 2025, with record heatwaves from the Mediterranean to the Arctic region. This caused rapid loss of glacier mass and snow cover, according to the latest State of the European Climate report by the World Meteorological Organization (WMO) released on Thursday. All of Europe’s glaciers saw a net mass loss, with Iceland recording its second-largest glacier loss on record. The continent experienced dangerously high air temperatures, drought, heatwaves and record ocean temperatures. This has translated into economic and biodiversity loss affecting countries and ecosystems across the continent. “Europe is the fastest-warming continent, and the impacts are already severe. Almost the whole region has seen above-average annual temperatures,” said Florian Pappenberger, Director-General of the European Centre for Medium-Range Weather Forecasts (ECMWF), an inter-governmental organisation that contributed to the report along with WMO. Also read: Europe is World’s Fastest Warming Continent With Record Temperatures in 2024 Europe is warming twice as fast as the global average Europe is now the fastest-warming continent, warming twice as fast as the global average. The impact of the temperature increases is most visible in the coldest regions, such as the Arctic and the Alps. Snow and ice play a critical role in slowing climate change by reflecting sunlight into space in what is known as the albedo effect. “In 2025, sub-Arctic Norway, Sweden and Finland recorded their worst heatwave on record with 21 straight days and temperatures exceeding 30°C within the Arctic Circle itself,” Pappenberger of ECMWF said. This also pushed up temperatures within and adjacent to the Arctic Circle to over 30°C, peaking at 34.9°C in Frosta, Norway. Ironically, low levels of air pollution in Europe allow more solar radiation to reach the surface, leading to a higher rate of warming. The number of cold stress days when temperatures drop below normal is also reducing. Nearly 90% of the continent experienced fewer cold stress days than average, and minimum temperatures remained above average for most of the year. Hot, dry conditions resulted in more wildfires. A record total area of around 1,034,000 hectares was burnt across Europe – an area larger than Cyprus. Spain, Cyprus, the United Kingdom, the Netherlands, and Germany recorded their highest wildfire emissions on record in 2025. Record loss of glacier mass Glaciers across Europe lost mass in 2025, with the highest loss recorded in Iceland. The Greenland Ice Sheet, which is the largest ice mass in the northern hemisphere and covers 80% of Greenland, lost 139 gigatonnes (139 billion tonnes) of ice. This is equivalent to 1.5 times the volume stored in all glaciers in the European Alps. Such ice loss contributes to rising global sea levels, with every centimetre increase exposing an additional six million people to coastal flooding. Overall, snow cover was 31% below average, affecting 1.32 million square kilometres, which is equivalent to the combined area of France, Italy, Germany, Switzerland, and Austria. “The ESOTC 2025 paints a stark picture: the pace of climate change demands more urgent action. With rising temperatures, and widespread wildfires and drought, the evidence is unequivocal; climate change is not a future threat, it is our present reality,” Samantha Burgess, Strategic Lead for Climate at ECMWF said. Rising ocean heat, reducing river flow Nearly 86% of European waters saw strong marine heatwaves in 2025. Oceans absorb 90% of the atmosphere’s excess heat due to the burning of fossil fuels. In 2025, Europe’s sea surface temperature was the highest on record. Around 86% of the region experienced strong marine heatwaves, disrupting fish and the ocean plants. Changes in rainfall and snowfall patterns have also affected the flow in 70% of Europe’s rivers. In May 2025, around half of Europe (53%) was affected by drought conditions. “Maintaining our own state-of-the-art, reliable data records of our Earth system is vital for making informed policy decisions in our rapidly changing climate. Copernicus is pivotal to help us preserve our sovereignty, our environment, food systems, safety, and economy,” said Mauro Facchini, Head of the European Commission’s Copernicus, is the European Union’s Earth Observation Programme. Renewable growth and actionable items for policymakers The share of renewables in Europe’s energy mix has gone up, supported by the growth in solar energy. A silver lining in the report is the growth of renewable energy, which in 2025 supplied nearly half (46.4%) of Europe’s electricity. Solar power contributed around 12.5% of this, a new regional record. Countries have begun to see energy security as a national security issue, and that appears to be one of the reasons driving the growth of renewables, including the adoption of nuclear energy at a higher rate compared to recent decades. Another positive was that by the end of 2025, around half of the European Biodiversity Strategy 2030’s recommended actions were in place or completed. The strategy is a European Union plan to restore the continent’s biodiversity. The report highlighted initiatives like Ireland’s network of marine protected areas, Armenia’s biodiversity finance plan, and Iceland’s funding to assist in recovering wetlands as examples of policy interventions that can help arrest biodiversity loss. Image Credits: Unsplash/Jochen Bückers, WMO. Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Making Better Vaccine Choices in a Shifting Global Health Landscape 27/04/2026 Charlie Weller A baby gets a first dose of the measles, mumps and rubella (MMR) vaccine at a health center in Côte d’Ivoire. Global aid cuts have left countries struggling to meet childhood vaccine schedules. In an era of big global health budget cuts that often demand tough choices, identifying vaccine needs and priorities at national level is increasingly important. As we observe World Immunization Week, it’s time to recognize the pivotal role that National Immunization Technical Advisory Groups (NITAGs) can play in guiding effective, evidence-based decisions – alongside global guidance from the World Health Organization. From infancy to old age, vaccines are a life-saving tool. Over the past 50 years, vaccines have saved more than 150 million lives. They play a decisive role in keeping us safe from diseases through childhood, strengthening our immune responses in adulthood, and keeping us out of hospital in our older years. Immunisation currently prevents 3.5 million to 5 million deaths every year from diseases like tetanus, pertussis, influenza, and measles. Without vaccines, diseases consigned to the past could resurge in our present. Funding cuts and reduced resources are increasing barriers to vaccine research and development, as well as equitable access to immunisation – including the routine vaccination of young children in low- and middle-income countries. This reduction in support and resources is forcing organisations like the World Health Organization and Gavi, the Vaccine Alliance, to rethink how they operate. Vaccine decision-making is no longer about access alone; it’s about prioritisation under constraints. (Left to right columns). Deaths averted, years of life saved, and years of full health gained due to vaccination. From global guidance to national decision-making Many countries still rely heavily on vaccine recommendations made by the WHO through the Strategic Advisory Group of Experts on Immunization (SAGE). While being scientifically robust and relevant they do not always reflect the specific needs, challenges or health systems of individual countries. With global health funding undergoing dramatic reductions, countries and regions most affected by infectious diseases are facing difficult decisions about which diseases to prioritise and how best to procure and roll-out vaccines to maintain even fuller vaccination schedules. This greater emphasis on country-level decision-making is appropriate – countries affected by diseases are best placed to make decisions on how to tackle them. However, it takes time to build expertise and evidence, and responsibility is being decentralised faster than this capacity can be developed, with experts required to wear multiple hats. This is not merely a technical challenge, but a political and operational one. It requires a reshaping of power and accountability in global health structures. filling gaps in infrastructure to support more national and regional decision-making. SAGE Executive Secretary Joachim Hombach presents updates on WHO vaccine recommendations at a 2025 briefing. While such global guidance remains critical, a greater emphasis on country-level decision-making is also appropriate. Regional decisions need regional expertise Building regional sharing of expertise is now as critical as supply chains. This is where advisory groups such as the National Immunization Technical Advisory Groups (NITAGs), can play a pivotal role in guiding effective, evidence-based decisions. Each country’s NITAGs expertise differs, but their aim is the same – multidisciplinary independent experts assess whether international knowledge is applicable and relevant to local contexts, informing appropriate policy recommendations at a national level and bridging the gap between research and policy action. The impact of NITAGs can be felt quickly, allowing the introduction of specific vaccines that better suit the regional needs – whether it’s switching from one malaria vaccine to another in Nigeria, or the introduction of a Hepatitis B vaccine given at birth in Lesotho. For this model to work effectively, sustained funding is needed not just for research projects but to support policy-relevant expertise, enabling research to be translated into country-relevant recommendations. This is why Wellcome is investing in the African-led NITAG Support Hub, or NISH, which helps strengthen NITAGs across Africa. Through local evidence and support, and by sharing expertise and best practice via resource hubs, countries can be better prepared to navigate choices, including which of the increasingly robust array of lifesaving vaccines to prioritise, where, and how – all whilst aid and global health budgets are shrinking. Similarly, Gavi, The Vaccine Alliance has introduced ‘The Gavi Leap’ – a new operating model aiming to support country self-reliance to transition away from donor-led systems. Gavi Leap is increasing resources to help countries decide their own priorities, financing and delivery of vaccines with the long-term goal of immunisation sustainability. The intervention trade-offs A Kinshasa neighbourhood water point in DR Congo. Better WASH practices can complement cholera vaccination efforts in fighting the deadly disease. Amidst global instability, decision-makers increasingly need to balance the benefits of investing in one vaccine over another, as well as balancing the costs of vaccine procurement and distribution with spending on other interventions such as diagnostics and therapeutics, surveillance and health system strengthening. For example, while oral cholera vaccines alone protect individuals against the disease, and water, sanitation and hygiene (WASH) alone reduces the amount of bacteria in the environment, studies suggest that combining the oral cholera vaccine with improved household WASH leads to optimal protection. Oral cholera vaccination campaign in Democratic Republic of Congo, December 2023. There is a tricky balance to strike, taking into account factors such as available resources; behavioural attitudes to interventions; the benefits and risks of mass immunisation campaigns; and the needs of vulnerable, under-resourced communities. And any public health policies must take a long-term view, with the ability to adapt to changing circumstances – such as the emergence of new outbreaks, new pathogen variants, and new forms of disease resistance. Diverse expertise combined with awareness of local needs and barriers is essential to ensure vaccines are neither over-prioritised nor underused. Global health will, and must, be a global effort, and international guidance remains essential. But it cannot replace regional and national judgement and local knowledge of community needs and challenges. Investment in expertise means equitable vaccine policies With tightening global funding, choices between vaccines and other essential health interventions are unavoidable. Doing so without investment in more localised expertise is not. Investing in national and regional advisory capacity, knowledge-sharing and long-lasting expertise is not a luxury, it is the foundation of smarter, fairer vaccine decisions in an increasingly constrained world. Charlie Weller is the Head of Prevention in Wellcome’s Infectious Disease team. Since 2016, she has led the team to develop new and improved vaccines and antibodies – from managing the research and funding response to the Ebola epidemic of 2014-2015, to helping the co-founding of the Coalition for Epidemic Preparedness Innovations (CEPI), which is investing in new vaccine development that protects the world from epidemic and pandemic threats. Image Credits: UNICEF, Shattock A, Johnson H, Sim S et al.,The Lancet, May 2024, E. Fletcher/Health Policy Watch , Eduardo Soteras Jalil/ WHO, Esther Nsapu/Wellcome Trust. UN Deadlock and Iran War Oil Shocks Push 54 Nations to Chart Fossil Fuel Phase Out 27/04/2026 Stefan Anderson Governments, civil society and indigenous communities gather in Santa Marta Colombia to address the hurdle decades of UN climate summits have failed to clear: phasing out fossil fuels. More than 50 countries are gathering this week on Colombia’s Caribbean coast to launch a coalition for phasing out fossil fuels, as a third month of war in Iran exposes the costs of a global economy run on the oil, gas and coal driving the climate crisis that decades of deadlocked UN climate talks have failed to curb. No outcome text, funding or binding legal commitments are expected to come out of Santa Marta. Yet that the meeting exists at all – and is attended by several major fossil fuel powers including Australia, Canada, the United Kingdom, Nigeria and Norway – is a source of optimism for observers hoping it may be the start of a wind change in climate politics. The final tally of 54 states attending the first-of-its-kind conference is more than double the number of founding signatories who joined Colombia’s initiative as UN climate talks collapsed at COP30 in Belém last November. Combined, the coalition in Santa Marta represents around half of global GDP and 2.5 billion people, roughly a third of the global population. “The task for those attending is clear: not to debate whether to phase out fossil fuels but to determine how to do it – rapidly, fairly, and in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. “It has never been more urgent to leave behind oil, gas and coal than it is today.” Climate Change Is Here, And It’s Killing Millions Ministers and high-level delegations arrive on Tuesday and will negotiate through Wednesday evening. The primary goal, its host Colombia said, is “to launch an international coalition to jointly implement the transition away from fossil fuels.” “We need a multilateralism that is more deeply rooted in the people and not just in governments, biases or economic lobbying,” Colombian environment minister Irene Velez-Torres told AFP. “We need new alignments, new alliances. In that sense, we are a new power today,” she said, pointing to the global coalition in attendance. Fossil fuels are also driving a mounting public health catastrophe. Heat exposure now claims an estimated 546,000 lives annually, while air pollution from burning oil, gas and coal kills another 2.5 million people each year, according to the Lancet Countdown on health and climate change. “Fossil fuels are causing immediate harm,” said Jeni Miller, executive director of the Global Climate and Health Alliance, a consortium of more than 250 health organisations that submitted recommendations to the conference. “Phasing them out is not only about protecting the planet but also about saving lives in the near term, reducing strain on health systems, and creating greener, more just, and healthier societies.” The talks will aim to allow space for constructive negotiations among like-minded nations, unencumbered by the consensus-based UN system. Agreements at COPs require all 200 nations to sign off on the final text, a system which has allowed petrostates to block progress for decades. “The consensus methodology has resulted in a de facto veto against countries like Colombia that want more ambitious discussions on decisions, particularly related to fossil fuels,” Velez-Torres said. Who’s at the party? Boats sit along the Caribbean coastline of Santa Marta, Colombia, host city of the conference. Participants in Santa Marta include the European Union, the United Kingdom, small island developing states on the frontlines of sea level rise, several dozen developing nations, and COP31 co-hosts Turkey and Australia. Organisers said more than 2,600 civil society and indigenous community representatives are also in attendance in-person and online. Fossil fuel superpowers in the Gulf, the United States and Russia are not present. The world’s other biggest emitters including China, India, Iran and Japan, will also be absent. But unlike UN proceedings, which invite all member states by default, the tone struck by Colombia and the Netherlands is different: if you’re not going to help, don’t come. “We are not going to have boycotters or climate denialists at the table,” Vélez-Torres told the Guardian. “Whatever nations have not yet taken that decision, then this is not the space for them.” “Despite our differences, all participants agree on the need to prioritise science and to move forward, urgently and in a coordinated manner, toward phasing out the production and consumption of natural gas, coal, and oil,” she added in a statement shared by the summit presidency. The United States, for example, was not even invited. The Trump administration declined to send any delegation to COP30 in November — the first US absence from a UN climate summit since talks began in 1993 — and exited the Paris Climate Accord for a second time after President Donald Trump, who denies climate change, returned to office. “The president has been clear that the United States will not participate in the bogus climate agenda,” Taylor Rogers, a White House spokeswoman, said in a statement to the New York Times. Green momentum Delegates from the 24 founding nations of the fossil fuel phase-out conference initiative celebrate at COP30 in Belém, Brazil. As the US-Israeli war on Iran enters its third month with no clear end in sight, its shockwaves have caused the largest energy crisis in history – one that International Energy Agency chief Fatih Birol recently described as “worse than those of 1973, 1979, and 2022 combined.” It is the second major war-driven oil price shock in less than five years, after Russia’s invasion of Ukraine, and the crisis third since COVID-19 shut the global economy in 2019. That cascade of global crises is reshaping how COP negotiators are approaching this year’s summit. “No one has said this crisis is a reminder that we need to be more reliant on fossil fuels,” said Chris Bowen, Australia’s climate minister and lead negotiator for COP31, in his first interview in the role with the Guardian. “There’s a real appetite to emphasise reliability and energy sovereignty this year, and I think that does open up more opportunities for COP31.” The new war makes Colombia’s conference notably prescient, demonstrating the stability renewables could offer energy systems insulated from oil shocks. Wind gusts and sun rays – unlike roughly 20% of the world’s oil, gas and fertilizer – cannot be blocked in the Strait of Hormuz. “Sunlight travels 93 million miles to reach the earth,” environmentalist Bill McKibben wrote in a recent analysis. “None of them through the Strait of Hormuz.” Green momentum is visible around the world. Amid the Iran war, China smashed its previous solar technology export record by 50% in March, with the largest growth in Asian and African countries most reliant on Middle East fossil fuels, according to the energy think tank Ember. Last year, electricity from low-carbon sources overtook coal for the first time, and solar power generation rose 33% in 2025 as fossil fuel generation remained flat, Ember found. “Fossil shocks are boosting the solar surge,” said Euan Graham, a lead analyst for the Ember report. “Solar has already become the engine of the global economy, and now the current fossil fuel price shocks are taking it up a gear.” Some analysts have suggested developing nations may turn to home-produced coal to offset the shock, but solar is simply more competitive on cost and growth in the long- and short-term, Birol said. “COPs are unlikely now to be Paris or Copenhagen — outstanding successes or heartbreaking failures,” Bowen added. “COPs are more likely to be incremental progress. The question is how big that progress is.” Fossil fuel superpowers reap billions from crisis Russian oil companies are on course to make over $23 billion in additional profits this year due to the oil crisis, replenishing Putin’s wartime coffers as his invasion of Ukraine presses on. Yet even as renewables surge, windfall profits from the oil crisis continue to flow into the coffers of nations pivotal to blocking UN climate agreements. Russia, the United States and Saudi Arabia stand to gain the most: billions in new funding for Vladimir Putin’s war chest amid a grinding war in Ukraine, $60 billion in projected windfall profits for US oil and gas, and soaring values for state-owned oil giant Saudi Aramco despite major damage to its infrastructure in the war. A climate-forward shift from this axis of obstruction at COP31 — its strategy now vindicated by the crisis — is unlikely. The world’s top 100 oil and gas companies have earned an additional $30 million in profits per hour since the Iran war began. The oil and gas industry has made around $1 trillion in annual profits for over five decades, making it history’s most profitable industry. The same constellation of fossil fuel nations derailed hopes for a legally binding plastics treaty in August. With energy demand for fossil fuels falling, the industry is increasingly rerouting oil and gas into plastic and petrochemicals, making production limits in any treaty an existential threat. As coffers at ExxonMobil, Saudi Aramco and Rosneft fill, the World Food Programme estimates 45 million people will be pushed into hunger as a result of the oil and fertilizer crisis, with the toll potentially rising to record levels. Out of the ashes of Bélem: a coalition of the willing? As leaders gather at #SantaMarta conference on Transitioning Away from Fossil Fuels, fossil fuel giants are set to make nearly $3,000 every second in 2026—$94B that could power 50M people in Africa with solar. This isn’t normal, and it’s certainly not fair.#MakeRichPollutersPay pic.twitter.com/3U7k6onGUl — Oxfam in Africa (@OxfaminAfrica) April 27, 2026 Colombia launched the initiative in the final hours of COP30 in Belém, Brazil, when standoffs between countries supporting more ambition, and those blocking it, sent the summit into freefall. Two weeks of intensive negotiations ended in no concrete financial or legal outcomes from the much-hyped meeting in the Amazon – whose gradual is an iconic symbol of climate change. The frustration from that collapse spurred Colombia to launch the last-minute call for a fossil fuel phase-out conference, which at the time drew just 24 signatures from the 200 nations present. With 54 countries attending this week, the shape of Colombia’s initiative recalls a similar coalition that took years to build during negotiations for a legally binding plastic pollution treaty. That alliance, the High Ambition Coalition, had 20 founding members when talks opened in Paris in 2022. By the final round in Geneva in August, its then 75 members had rallied some 120 nations behind core binding provisions, including phasing out harmful chemicals from plastic production. That treaty ultimately fell short — blocked by the same axis of obstruction, this time led by Saudi Arabia and flanked by the US, Russia and Iran — but the negotiations produced real movement in global cooperation and national policymaking. Campaigners are aiming for the the same arc of momentum to be played in the fossil fuels arena now but more successfully. The big prize would be a treaty modelled on what the plastics coalition tried, but failed, to build, this time aimed at production limits on oil, gas and coal. “Santa Marta must support a coalition of the doers to recognise and remove legal barriers to halt oil and gas expansion — particularly offshore — and to pursue effective international cooperation on fossil fuel phase-out, through the future negotiation of a Fossil Fuel Treaty,” Reisch said. “Phasing out fossil fuels is not just a scientific necessity and a legal obligation, it’s also a critical opportunity to break free from a destructive system.” Image Credits: Ben Wicks, Yves Alarie. Developed Countries Propose ‘Hybrid’ Model Ahead of Pandemic Agreement Talks 26/04/2026 Kerry Cullinan IGWG negotiators (clockwise from top L): Nurhafiza Hamza (Malaysia), moderator Guilherme Faviero (AIDS Health Foundation), Jean Karydakis (Brazil), Taime Sylvester (Namibia), Eirik Rodseth Bakka (Norway) and Adeel Mumtaz Khokhar (Pakistan). Yet another negotiating session on the outstanding annex of the Pandemic Agreement begins at the World Health Organization’s (WHO) headquarters on Monday (27 April) – and developed nations have presented a “hybrid” solution in an attempt to find consensus. The “hybrid” proposal consists of a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. Adeel Mumtaz Khokhar, First Secretary to the Permanent Mission of Pakistan in Geneva, confirmed that a “hybrid” proposal had been presented to developing countries by some developed countries, but declined to name them. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The outstanding annex will set out terms for a pathogen access and benefit-sharing (PABS) system that ensures all countries have access to countermeasures to combat a pandemic or public health emergency of international concern (PHEIC) – unlike during COVID-19 when rich countries hoarded scarce vaccines. “We have been hearing rumours about this hybrid system for the past two IGWG [Intergovernmental Working Group] meetings, and finally, some developed country negotiator took pity on us and presented it,” Khokhar told a high-level webinar hosted by the University of Miami’s Public Health Policy Lab and AIDS Healthcare Foundation (AHF) last week. The proposal envisages two categories for biological material, Khokhar explained. To access one category, countries and manufacturers will “have to follow certain terms and conditions”, and these will be included in the PABS system. No terms or conditions apply to the other category of material, including benefit-sharing obligations. However, Third World Network (TWN), a civil society alliance tracking the negotiations, says that the hybrid system proposed by developed countries also envisages a split between information sharing and benefits. “Developed countries expect developing countries to share pathogen samples and sequence information freely, while deferring benefit-sharing to future negotiations between WHO and pharmaceutical manufacturers,” writes TWN in a recent brief. Maintains the status quo For Khokhar, the hybrid proposal “is essentially the status quo” as it allows parties to “share the way they want to share”. “So I’m not sure how fundamentally the needle is moved by this proposal. All I can understand from this proposal is that they want to retain and preserve the status quo, which, from a developing country negotiations perspective, is a disappointment.” Nurhafiza Hamza, Minister Counsellor for Health at Malaysia’s Permanent Mission to Geneva, explained that developing countries want “a set of mandatory benefit-sharing that is acceptable to different categories of users of the PABS system” – member states and pharmaceutical companies – during health emergencies. “If manufacturers have VTDs during a PHEIC or pandemic emergency, they should share,” said Hamza. “It is important to get some mandatory benefit sharing and not a menu of options, where manufacturers can pick and choose.” Kicking the can down the road? France’s Ambassador Anne-Claire Amprou, co-chair of the talks, and WHO Director-General Dr Tedros at the conclusion of the Pandemic Agreement talks. Jean Karydakis, Counsellor in Brazil’s Mission in Geneva, acknowledged that the positions of the different groups – primarily developed countries versus developing countries – are fairly entrenched. “We won’t change other countries’ positions at this time,” he acknowledged. “The question now is whether we can find possible creative language, also bearing in mind that we will have a Conference of the Parties (COP) later on that will need to revisit and detail further what we cannot agree right now.” Karydakis also asserted that “90% of of the text is already agreed in the Pandemic Agreement, and the Pandemic Agreement was already adopted. “ But the PABS system was a contentious issue that evaded negotiators, who packaged it into an annex and kicked it down the road to new negotiations. This enabled the World Health Assembly to adopt the Pandemic Agreement last year, described by some observers as the Pandemic Agreement Lite precisely because it dodged the detail about PABS. Adopting a vague PABS annex and kicking further details down the road again – this time to the COP – might save face for multilateralism. But it simply delays the adoption of the Pandemic Agreement to yet another set of talks, leaving all member states vulnerable to public health emergencies in the meantime. Standard contracts? Developing countries want the annex to include a standard contract to govern access to biological material and digital sequencing, including benefit-sharing obligations. But Khokhar said that the IGWG Bureau and “other colleagues” have expressed that “a full standardised contract may not be the appropriate way”, as it is hard to predict what – if any – VTDs may be developed as a result. “Fair enough,” he said, adding that developing countries are prepared to explore the inclusion of a “basic contract” followed by a PABS contract, if a party has developed a medical countermeasure. “But what is their answer to this suggestion? Let’s have an open and a closed system. So, in this endeavour to try and find and create a multilateral system, we are actually going back to our national systems… What new system are we creating here? We’re creating nothing new?” For TWN, the lack of “contractually enforceable legal obligations for recipients of PABS materials and sequence information “will add to the legal uncertainty, as benefit-sharing will depend on the WHO concluding contracts with manufacturers. Namibian negotiator Taime Sylvester said that the funders of research in developing countries are “overwhelmingly high-income country governments and foundations”. They could “include PABS compliance as a condition of their grants,” said Sylvester, pointing to the example of the European Union’s Horizon Europe (2021–2027), its funding programme for research and innovation. This requires researchers to commit to Nagoya Protocol compliance, which mandates fair benefit-sharing from the use of genetic resources. Prospects for agreement Norwegian Health Counsellor Eirik Rodseth Bakka acknowledged that there are “significant outstanding issues, and I think as a collective, we do need to see significant progress next week”. However, he stressed that member states have the opportunity to “correct some of those inequities from the COVID-19 pandemic,” especially early access to vaccines for low- countries and lower-middle-income countries, and enabling “to the extent possible that there is more technology transfer and access to access to manufacturing capacity.” Karydakis expressed hope that “we will get this by May”, adding that talks may need to continue alongside the World Health Assembly in late May, the deadline for the annex. He also joked that night sessions were necessary to get people tired and hungry and “only able to leave the room when the deal is reached.” Sylvester said that Namibia believes that “a fair, functional, legally grounded PABS system” is possible and will assist both the global south and the global north need this functional system to succeed. So we we believe it. We believe that it can happen which is above and beyond, or we’re not asking any country to stand to a higher standard. We’re asking the same standards. Malaysia’s Hamza described the PABS system as “the litmus test for equity”. “We will have to see whether states will come in next week and design a PABS system that would actually make an improvement in the current status quo.When the Group for Equity gets together, the first thing we will assess is whether what we have agreed on, each paragraph, is really delivering equity.” Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Malaria Funding Crisis and Drug Resistance Compel African Investment 28/04/2026 Felix Sassmannshausen From left to right: Ambassadors Fancy Too (Kenya), Urujeni Bakuramutsa (Rwanda), Arthur Kafeero (Uganda), Pratana Disyatat (Thailand), and moderator Dr Michael Adekunle Charles (RBM Partnership). GENEVA – As global health leaders gathered in Geneva on Monday to commemorate this year’s World Malaria Day, an advocacy forum featuring high-level diplomats addressed the rising threat of antimalarial drug resistance. Celebrations of medical progress and clinical discussions quickly gave way to discussion about a rapidly escalating malaria funding crisis, with more funding cuts are on the horizon. Quantifying the human cost of this stagnation, Dr Michael Adekunle Charles, moderator of the event and CEO of the RBM Partnership to End Malaria, noted that Africa is fundamentally off track to meet elimination targets. “It is the equivalent of five jumbo jets crashing on a daily basis – in the 21st century in the year 2026,” he said. The high-level event, co-hosted by the RBM Partnership to End Malaria and Medicines for Malaria Venture (MMV), balanced stark clinical realism with a pragmatic call to action. Faced with retreating Western donors and mutating parasites, African diplomats demanded a decisive shift towards health sovereignty, local manufacturing, and integrated regional investments. The critical malaria funding gap is already huge, yet it is set to widen, with further cuts on the horizon. The rise in resistance coincides with the financial landscape for global health moving from temporary supply disruptions to deep, structural declines in official development assistance. In 2024, total malaria funding reached $3.9 billion, a mere 42% of the $9.3 billion required annually to remain on track toward global elimination targets, directly compounding the malaria funding crisis. Moderator Michael Adekunle Charles points to necessary investments. Acknowledging the shifting financial landscape, Charles noted that discussions of global health policy are obsolete without addressing the immediate need for domestic financial commitments. “If you have a conversation without talking about financing right now, then you have missed the topic entirely,” said Charles in an interview with Health Policy Watch following the panel. “But it is about investments, not just funding from the West,” he added. Before the financial realities fully set in, attendees paused to reflect on the visceral, human toll of the disease that continues to devastate rural communities, where the disease accounted for over 265 million clinical cases across Africa in 2024, according to the WHO World Malaria Report. Sharing his own experience from the podium, Ambassador Arthur Kafeero, deputy permanent representative of Uganda to the United Nations, highlighted his visceral childhood memories of surviving severe malaria during the panel discussion. Biological threats demand urgent containment Confirmed partial antimalarial drug resistance across Africa threatens to undo years of progress. Despite remarkable pharmacological victories, the overarching malaria funding crisis threatens to severely undermine current front-line treatments, as mutating parasites rapidly spread across the African continent and delay parasite clearance. Charlotte Rasmussen, technical officer at the World Health Organization, took the stage early in the event to confirm that artemisinin partial resistance is steadily spreading across Africa. She clarified that while artemisinin-based combination therapies (ACTs) still remain highly effective across most of the continent provided the partner drug works, the undetected spread of resistant strains places a greater burden on these partner drugs. Charlotte Rasmussen (WHO) warns about increasing partial drug resistance. This exacerbates the broader malaria funding crisis through prolonged illnesses and repeated hospital visits for patients failing to clear the parasite. “Any delay in the response would increase the impact, so the cost depends on how early we detect it and how effectively we respond,” said Rasmussen during her briefing. According to recent surveillance data, four African nations – Eritrea, Rwanda, Uganda, and the United Republic of Tanzania – have now officially confirmed artemisinin partial resistance. Genetic variations in the parasite have also compromised the accuracy of standard rapid diagnostic tests, necessitating enhanced, resource-intensive genomic surveillance networks that are increasingly difficult to finance and maintain amid the malaria funding crisis. If this genetic resistance is allowed to progress to full treatment failure, experts warn of a catastrophic surge in mortality that would entirely reverse decades of public health progress, potentially leading to more than 50 million treatment failures in the year 2060 alone. Mathematical modelling from Imperial College London suggests that delaying a transition to alternative therapies could rapidly overwhelm fragile medical infrastructure, costing affected nations well over $1 billion over the next 15 years. “The current funding gap means that we’re probably going to detect it more slowly and that we’re not going to be able to respond as effectively,” said Rasmussen during her presentation to the forum attendees. ‘More budget cuts will come’ Preliminary data for 2025 and projections for 2026 reveal a steep, structural decline in total official development assistance, also severely affecting the fight against malaria. “Now the situation has changed, changes are huge, and more budget cuts will come,” said Erika Placella, representing the Swiss Development Cooperation, during a virtual address broadcast to the room. Traditional donor nations, severely impacted by domestic fiscal pressures, are demanding a complete reset of the highly fragmented global health architecture in response to the macroeconomic malaria funding crisis. Representatives from major international financing bodies warned attendees that the era of relying heavily on external funding for basic disease control is definitively ending, forcing a necessary evolution in international diplomacy. Erika Placella warned of further funding cuts in a virtual address. Western donors are urging more structural reform, arguing that supporting standalone, siloed disease programmes is no longer economically viable or sustainable in the current constrained fiscal environment. They are also pushing for more integrated primary care investments that strengthen entire national health systems to weather the ongoing malaria funding crisis and deliver holistic maternal and child care. “It’s now time to talk about functions and not about institutions,” said Placella during her virtual address to the forum. Sovereign science counters donor retreats This unprecedented reduction in external aid has catalysed a powerful movement towards African health sovereignty, fundamentally reshaping how the continent intends to manage the ongoing malaria funding crisis. High-level political commitments, including the African Union roadmap and the Yaoundé Declaration, are establishing the framework for this transition, although leaders acknowledge that domestic financing must shift rapidly from aspiration to obligation to ensure a sustainable path forward independent of foreign aid. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty Regional health ministries are prioritizing the rapid expansion of localized production facilities to secure medical supply chains against future international funding shocks resulting from the malaria funding crisis. “We need to build or strengthen local and regional manufacturing capacity to improve supply security,” said Uganda’s UN representative Kafeero during the panel discussion. To ensure next-generation antimalarials reach patients before current treatments completely fail, global health leaders are also stressing the critical need for streamlined regulatory pathways across the continent. Rather than waiting for standard, lengthy approval processes, experts argue that African institutions must take the lead in bringing new drugs to market. MMV CEO Martin Fitchet advocated for “coordinated and accelerated regulatory approval and review using the new AMA Africans medicine’s agency to usher and speed these agents along in the targeted geographies where they could have the most impact where we know this problem is the greatest”. Global health leaders and diplomats gather in Geneva for an advocacy forum to tackle the escalating malaria funding crisis. There was broad consensus that the push for health sovereignty must be underpinned by collaborative regional networks, such as those within the East African Community, to effectively track migrating parasites and align cross-border treatment protocols. By pooling technical expertise and sharing genomic surveillance data in real-time, neighbouring countries can deploy joint responses before localized resistance outbreaks escalate into wider regional crises. Ambassador Pratana Disyatat, deputy permanent representative of Thailand to the United Nations, discussed how her region is manage migrating parasites. “We have targeted interventions for high-risk populations such as along the borders we have mobile malaria clinics. We have a cross border referral systems,” said Disyatat. Ambassador Fancy Too (Kenya) emphasizes strengthening community health. Several African nations are already taking aggressive domestic steps to update their treatment protocols in response to the rapidly changing biological and financial landscape. Kenya, for instance, has recently updated its national malaria policy and developed a costed plan following its early implementation of multiple first-line therapies (MFT), ensuring its health systems can adapt swiftly to emerging drug resistance markers while training community health workers. Similarly, Rwanda has officially adopted a national strategy to deploy MFT to actively slow the spread of resistance. “We are trying to improve compliance to current treatments by strengthening community health programs and training the health workers,” said Kenya’s Ambassador Fancy Too. Panelists encouraged public health officials to integrate informal medical providers and private medicine retailers into national surveillance systems. With a large proportion of patients seeking initial care outside public facilities, engaging this sector is essential to monitor drug efficacy, track supply chains, and protect highly vulnerable demographics. Innovating amidst severe financial shortfalls Expanding regional genomic surveillance and local R&D is essential to combat emerging drug-resistant malaria strains. Funding the robust research required for future innovations remains a persistent challenge, demanding creative financing and a willingness to prioritize long-term pharmaceutical development alongside immediate clinical access. Innovators are rapidly developing triple artemisinin-based combination therapies to actively protect existing partner drugs from the highly resilient parasite resistance currently spreading across the continent, alongside long-acting preventive injections to protect vulnerable populations from contracting the disease across an entire season. Health leaders explicitly warn that halting this critical research pipeline to cover immediate budgetary shortfalls caused by the malaria funding crisis would result in catastrophic casualties in the near future. To secure the fight against malaria, scaling up continental pharmaceutical industries relies heavily on empowering institutions like the African Medicines Agency to expedite regulatory approvals for these next-generation therapeutic drugs. MMV’s Fitchet bluntly acknowledged the daunting reality of the situation to forum attendees. “I don’t know where the money is going to come from, but it’s imperative that we invest in the right programmatic roll out to protect the agents we have now and in the investment in the future,” he urged. “If we don’t invest in access now, people will die. If we don’t invest in R&D for now as well, many more will die tomorrow.” Image Credits: Felix Sassmannshausen/HPW, WHO, WHO/Felix Sassmannshausen, OECD, RBM. ‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Making Better Vaccine Choices in a Shifting Global Health Landscape 27/04/2026 Charlie Weller A baby gets a first dose of the measles, mumps and rubella (MMR) vaccine at a health center in Côte d’Ivoire. Global aid cuts have left countries struggling to meet childhood vaccine schedules. In an era of big global health budget cuts that often demand tough choices, identifying vaccine needs and priorities at national level is increasingly important. As we observe World Immunization Week, it’s time to recognize the pivotal role that National Immunization Technical Advisory Groups (NITAGs) can play in guiding effective, evidence-based decisions – alongside global guidance from the World Health Organization. From infancy to old age, vaccines are a life-saving tool. Over the past 50 years, vaccines have saved more than 150 million lives. They play a decisive role in keeping us safe from diseases through childhood, strengthening our immune responses in adulthood, and keeping us out of hospital in our older years. Immunisation currently prevents 3.5 million to 5 million deaths every year from diseases like tetanus, pertussis, influenza, and measles. Without vaccines, diseases consigned to the past could resurge in our present. Funding cuts and reduced resources are increasing barriers to vaccine research and development, as well as equitable access to immunisation – including the routine vaccination of young children in low- and middle-income countries. This reduction in support and resources is forcing organisations like the World Health Organization and Gavi, the Vaccine Alliance, to rethink how they operate. Vaccine decision-making is no longer about access alone; it’s about prioritisation under constraints. (Left to right columns). Deaths averted, years of life saved, and years of full health gained due to vaccination. From global guidance to national decision-making Many countries still rely heavily on vaccine recommendations made by the WHO through the Strategic Advisory Group of Experts on Immunization (SAGE). While being scientifically robust and relevant they do not always reflect the specific needs, challenges or health systems of individual countries. With global health funding undergoing dramatic reductions, countries and regions most affected by infectious diseases are facing difficult decisions about which diseases to prioritise and how best to procure and roll-out vaccines to maintain even fuller vaccination schedules. This greater emphasis on country-level decision-making is appropriate – countries affected by diseases are best placed to make decisions on how to tackle them. However, it takes time to build expertise and evidence, and responsibility is being decentralised faster than this capacity can be developed, with experts required to wear multiple hats. This is not merely a technical challenge, but a political and operational one. It requires a reshaping of power and accountability in global health structures. filling gaps in infrastructure to support more national and regional decision-making. SAGE Executive Secretary Joachim Hombach presents updates on WHO vaccine recommendations at a 2025 briefing. While such global guidance remains critical, a greater emphasis on country-level decision-making is also appropriate. Regional decisions need regional expertise Building regional sharing of expertise is now as critical as supply chains. This is where advisory groups such as the National Immunization Technical Advisory Groups (NITAGs), can play a pivotal role in guiding effective, evidence-based decisions. Each country’s NITAGs expertise differs, but their aim is the same – multidisciplinary independent experts assess whether international knowledge is applicable and relevant to local contexts, informing appropriate policy recommendations at a national level and bridging the gap between research and policy action. The impact of NITAGs can be felt quickly, allowing the introduction of specific vaccines that better suit the regional needs – whether it’s switching from one malaria vaccine to another in Nigeria, or the introduction of a Hepatitis B vaccine given at birth in Lesotho. For this model to work effectively, sustained funding is needed not just for research projects but to support policy-relevant expertise, enabling research to be translated into country-relevant recommendations. This is why Wellcome is investing in the African-led NITAG Support Hub, or NISH, which helps strengthen NITAGs across Africa. Through local evidence and support, and by sharing expertise and best practice via resource hubs, countries can be better prepared to navigate choices, including which of the increasingly robust array of lifesaving vaccines to prioritise, where, and how – all whilst aid and global health budgets are shrinking. Similarly, Gavi, The Vaccine Alliance has introduced ‘The Gavi Leap’ – a new operating model aiming to support country self-reliance to transition away from donor-led systems. Gavi Leap is increasing resources to help countries decide their own priorities, financing and delivery of vaccines with the long-term goal of immunisation sustainability. The intervention trade-offs A Kinshasa neighbourhood water point in DR Congo. Better WASH practices can complement cholera vaccination efforts in fighting the deadly disease. Amidst global instability, decision-makers increasingly need to balance the benefits of investing in one vaccine over another, as well as balancing the costs of vaccine procurement and distribution with spending on other interventions such as diagnostics and therapeutics, surveillance and health system strengthening. For example, while oral cholera vaccines alone protect individuals against the disease, and water, sanitation and hygiene (WASH) alone reduces the amount of bacteria in the environment, studies suggest that combining the oral cholera vaccine with improved household WASH leads to optimal protection. Oral cholera vaccination campaign in Democratic Republic of Congo, December 2023. There is a tricky balance to strike, taking into account factors such as available resources; behavioural attitudes to interventions; the benefits and risks of mass immunisation campaigns; and the needs of vulnerable, under-resourced communities. And any public health policies must take a long-term view, with the ability to adapt to changing circumstances – such as the emergence of new outbreaks, new pathogen variants, and new forms of disease resistance. Diverse expertise combined with awareness of local needs and barriers is essential to ensure vaccines are neither over-prioritised nor underused. Global health will, and must, be a global effort, and international guidance remains essential. But it cannot replace regional and national judgement and local knowledge of community needs and challenges. Investment in expertise means equitable vaccine policies With tightening global funding, choices between vaccines and other essential health interventions are unavoidable. Doing so without investment in more localised expertise is not. Investing in national and regional advisory capacity, knowledge-sharing and long-lasting expertise is not a luxury, it is the foundation of smarter, fairer vaccine decisions in an increasingly constrained world. Charlie Weller is the Head of Prevention in Wellcome’s Infectious Disease team. Since 2016, she has led the team to develop new and improved vaccines and antibodies – from managing the research and funding response to the Ebola epidemic of 2014-2015, to helping the co-founding of the Coalition for Epidemic Preparedness Innovations (CEPI), which is investing in new vaccine development that protects the world from epidemic and pandemic threats. Image Credits: UNICEF, Shattock A, Johnson H, Sim S et al.,The Lancet, May 2024, E. Fletcher/Health Policy Watch , Eduardo Soteras Jalil/ WHO, Esther Nsapu/Wellcome Trust. UN Deadlock and Iran War Oil Shocks Push 54 Nations to Chart Fossil Fuel Phase Out 27/04/2026 Stefan Anderson Governments, civil society and indigenous communities gather in Santa Marta Colombia to address the hurdle decades of UN climate summits have failed to clear: phasing out fossil fuels. More than 50 countries are gathering this week on Colombia’s Caribbean coast to launch a coalition for phasing out fossil fuels, as a third month of war in Iran exposes the costs of a global economy run on the oil, gas and coal driving the climate crisis that decades of deadlocked UN climate talks have failed to curb. No outcome text, funding or binding legal commitments are expected to come out of Santa Marta. Yet that the meeting exists at all – and is attended by several major fossil fuel powers including Australia, Canada, the United Kingdom, Nigeria and Norway – is a source of optimism for observers hoping it may be the start of a wind change in climate politics. The final tally of 54 states attending the first-of-its-kind conference is more than double the number of founding signatories who joined Colombia’s initiative as UN climate talks collapsed at COP30 in Belém last November. Combined, the coalition in Santa Marta represents around half of global GDP and 2.5 billion people, roughly a third of the global population. “The task for those attending is clear: not to debate whether to phase out fossil fuels but to determine how to do it – rapidly, fairly, and in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. “It has never been more urgent to leave behind oil, gas and coal than it is today.” Climate Change Is Here, And It’s Killing Millions Ministers and high-level delegations arrive on Tuesday and will negotiate through Wednesday evening. The primary goal, its host Colombia said, is “to launch an international coalition to jointly implement the transition away from fossil fuels.” “We need a multilateralism that is more deeply rooted in the people and not just in governments, biases or economic lobbying,” Colombian environment minister Irene Velez-Torres told AFP. “We need new alignments, new alliances. In that sense, we are a new power today,” she said, pointing to the global coalition in attendance. Fossil fuels are also driving a mounting public health catastrophe. Heat exposure now claims an estimated 546,000 lives annually, while air pollution from burning oil, gas and coal kills another 2.5 million people each year, according to the Lancet Countdown on health and climate change. “Fossil fuels are causing immediate harm,” said Jeni Miller, executive director of the Global Climate and Health Alliance, a consortium of more than 250 health organisations that submitted recommendations to the conference. “Phasing them out is not only about protecting the planet but also about saving lives in the near term, reducing strain on health systems, and creating greener, more just, and healthier societies.” The talks will aim to allow space for constructive negotiations among like-minded nations, unencumbered by the consensus-based UN system. Agreements at COPs require all 200 nations to sign off on the final text, a system which has allowed petrostates to block progress for decades. “The consensus methodology has resulted in a de facto veto against countries like Colombia that want more ambitious discussions on decisions, particularly related to fossil fuels,” Velez-Torres said. Who’s at the party? Boats sit along the Caribbean coastline of Santa Marta, Colombia, host city of the conference. Participants in Santa Marta include the European Union, the United Kingdom, small island developing states on the frontlines of sea level rise, several dozen developing nations, and COP31 co-hosts Turkey and Australia. Organisers said more than 2,600 civil society and indigenous community representatives are also in attendance in-person and online. Fossil fuel superpowers in the Gulf, the United States and Russia are not present. The world’s other biggest emitters including China, India, Iran and Japan, will also be absent. But unlike UN proceedings, which invite all member states by default, the tone struck by Colombia and the Netherlands is different: if you’re not going to help, don’t come. “We are not going to have boycotters or climate denialists at the table,” Vélez-Torres told the Guardian. “Whatever nations have not yet taken that decision, then this is not the space for them.” “Despite our differences, all participants agree on the need to prioritise science and to move forward, urgently and in a coordinated manner, toward phasing out the production and consumption of natural gas, coal, and oil,” she added in a statement shared by the summit presidency. The United States, for example, was not even invited. The Trump administration declined to send any delegation to COP30 in November — the first US absence from a UN climate summit since talks began in 1993 — and exited the Paris Climate Accord for a second time after President Donald Trump, who denies climate change, returned to office. “The president has been clear that the United States will not participate in the bogus climate agenda,” Taylor Rogers, a White House spokeswoman, said in a statement to the New York Times. Green momentum Delegates from the 24 founding nations of the fossil fuel phase-out conference initiative celebrate at COP30 in Belém, Brazil. As the US-Israeli war on Iran enters its third month with no clear end in sight, its shockwaves have caused the largest energy crisis in history – one that International Energy Agency chief Fatih Birol recently described as “worse than those of 1973, 1979, and 2022 combined.” It is the second major war-driven oil price shock in less than five years, after Russia’s invasion of Ukraine, and the crisis third since COVID-19 shut the global economy in 2019. That cascade of global crises is reshaping how COP negotiators are approaching this year’s summit. “No one has said this crisis is a reminder that we need to be more reliant on fossil fuels,” said Chris Bowen, Australia’s climate minister and lead negotiator for COP31, in his first interview in the role with the Guardian. “There’s a real appetite to emphasise reliability and energy sovereignty this year, and I think that does open up more opportunities for COP31.” The new war makes Colombia’s conference notably prescient, demonstrating the stability renewables could offer energy systems insulated from oil shocks. Wind gusts and sun rays – unlike roughly 20% of the world’s oil, gas and fertilizer – cannot be blocked in the Strait of Hormuz. “Sunlight travels 93 million miles to reach the earth,” environmentalist Bill McKibben wrote in a recent analysis. “None of them through the Strait of Hormuz.” Green momentum is visible around the world. Amid the Iran war, China smashed its previous solar technology export record by 50% in March, with the largest growth in Asian and African countries most reliant on Middle East fossil fuels, according to the energy think tank Ember. Last year, electricity from low-carbon sources overtook coal for the first time, and solar power generation rose 33% in 2025 as fossil fuel generation remained flat, Ember found. “Fossil shocks are boosting the solar surge,” said Euan Graham, a lead analyst for the Ember report. “Solar has already become the engine of the global economy, and now the current fossil fuel price shocks are taking it up a gear.” Some analysts have suggested developing nations may turn to home-produced coal to offset the shock, but solar is simply more competitive on cost and growth in the long- and short-term, Birol said. “COPs are unlikely now to be Paris or Copenhagen — outstanding successes or heartbreaking failures,” Bowen added. “COPs are more likely to be incremental progress. The question is how big that progress is.” Fossil fuel superpowers reap billions from crisis Russian oil companies are on course to make over $23 billion in additional profits this year due to the oil crisis, replenishing Putin’s wartime coffers as his invasion of Ukraine presses on. Yet even as renewables surge, windfall profits from the oil crisis continue to flow into the coffers of nations pivotal to blocking UN climate agreements. Russia, the United States and Saudi Arabia stand to gain the most: billions in new funding for Vladimir Putin’s war chest amid a grinding war in Ukraine, $60 billion in projected windfall profits for US oil and gas, and soaring values for state-owned oil giant Saudi Aramco despite major damage to its infrastructure in the war. A climate-forward shift from this axis of obstruction at COP31 — its strategy now vindicated by the crisis — is unlikely. The world’s top 100 oil and gas companies have earned an additional $30 million in profits per hour since the Iran war began. The oil and gas industry has made around $1 trillion in annual profits for over five decades, making it history’s most profitable industry. The same constellation of fossil fuel nations derailed hopes for a legally binding plastics treaty in August. With energy demand for fossil fuels falling, the industry is increasingly rerouting oil and gas into plastic and petrochemicals, making production limits in any treaty an existential threat. As coffers at ExxonMobil, Saudi Aramco and Rosneft fill, the World Food Programme estimates 45 million people will be pushed into hunger as a result of the oil and fertilizer crisis, with the toll potentially rising to record levels. Out of the ashes of Bélem: a coalition of the willing? As leaders gather at #SantaMarta conference on Transitioning Away from Fossil Fuels, fossil fuel giants are set to make nearly $3,000 every second in 2026—$94B that could power 50M people in Africa with solar. This isn’t normal, and it’s certainly not fair.#MakeRichPollutersPay pic.twitter.com/3U7k6onGUl — Oxfam in Africa (@OxfaminAfrica) April 27, 2026 Colombia launched the initiative in the final hours of COP30 in Belém, Brazil, when standoffs between countries supporting more ambition, and those blocking it, sent the summit into freefall. Two weeks of intensive negotiations ended in no concrete financial or legal outcomes from the much-hyped meeting in the Amazon – whose gradual is an iconic symbol of climate change. The frustration from that collapse spurred Colombia to launch the last-minute call for a fossil fuel phase-out conference, which at the time drew just 24 signatures from the 200 nations present. With 54 countries attending this week, the shape of Colombia’s initiative recalls a similar coalition that took years to build during negotiations for a legally binding plastic pollution treaty. That alliance, the High Ambition Coalition, had 20 founding members when talks opened in Paris in 2022. By the final round in Geneva in August, its then 75 members had rallied some 120 nations behind core binding provisions, including phasing out harmful chemicals from plastic production. That treaty ultimately fell short — blocked by the same axis of obstruction, this time led by Saudi Arabia and flanked by the US, Russia and Iran — but the negotiations produced real movement in global cooperation and national policymaking. Campaigners are aiming for the the same arc of momentum to be played in the fossil fuels arena now but more successfully. The big prize would be a treaty modelled on what the plastics coalition tried, but failed, to build, this time aimed at production limits on oil, gas and coal. “Santa Marta must support a coalition of the doers to recognise and remove legal barriers to halt oil and gas expansion — particularly offshore — and to pursue effective international cooperation on fossil fuel phase-out, through the future negotiation of a Fossil Fuel Treaty,” Reisch said. “Phasing out fossil fuels is not just a scientific necessity and a legal obligation, it’s also a critical opportunity to break free from a destructive system.” Image Credits: Ben Wicks, Yves Alarie. Developed Countries Propose ‘Hybrid’ Model Ahead of Pandemic Agreement Talks 26/04/2026 Kerry Cullinan IGWG negotiators (clockwise from top L): Nurhafiza Hamza (Malaysia), moderator Guilherme Faviero (AIDS Health Foundation), Jean Karydakis (Brazil), Taime Sylvester (Namibia), Eirik Rodseth Bakka (Norway) and Adeel Mumtaz Khokhar (Pakistan). Yet another negotiating session on the outstanding annex of the Pandemic Agreement begins at the World Health Organization’s (WHO) headquarters on Monday (27 April) – and developed nations have presented a “hybrid” solution in an attempt to find consensus. The “hybrid” proposal consists of a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. Adeel Mumtaz Khokhar, First Secretary to the Permanent Mission of Pakistan in Geneva, confirmed that a “hybrid” proposal had been presented to developing countries by some developed countries, but declined to name them. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The outstanding annex will set out terms for a pathogen access and benefit-sharing (PABS) system that ensures all countries have access to countermeasures to combat a pandemic or public health emergency of international concern (PHEIC) – unlike during COVID-19 when rich countries hoarded scarce vaccines. “We have been hearing rumours about this hybrid system for the past two IGWG [Intergovernmental Working Group] meetings, and finally, some developed country negotiator took pity on us and presented it,” Khokhar told a high-level webinar hosted by the University of Miami’s Public Health Policy Lab and AIDS Healthcare Foundation (AHF) last week. The proposal envisages two categories for biological material, Khokhar explained. To access one category, countries and manufacturers will “have to follow certain terms and conditions”, and these will be included in the PABS system. No terms or conditions apply to the other category of material, including benefit-sharing obligations. However, Third World Network (TWN), a civil society alliance tracking the negotiations, says that the hybrid system proposed by developed countries also envisages a split between information sharing and benefits. “Developed countries expect developing countries to share pathogen samples and sequence information freely, while deferring benefit-sharing to future negotiations between WHO and pharmaceutical manufacturers,” writes TWN in a recent brief. Maintains the status quo For Khokhar, the hybrid proposal “is essentially the status quo” as it allows parties to “share the way they want to share”. “So I’m not sure how fundamentally the needle is moved by this proposal. All I can understand from this proposal is that they want to retain and preserve the status quo, which, from a developing country negotiations perspective, is a disappointment.” Nurhafiza Hamza, Minister Counsellor for Health at Malaysia’s Permanent Mission to Geneva, explained that developing countries want “a set of mandatory benefit-sharing that is acceptable to different categories of users of the PABS system” – member states and pharmaceutical companies – during health emergencies. “If manufacturers have VTDs during a PHEIC or pandemic emergency, they should share,” said Hamza. “It is important to get some mandatory benefit sharing and not a menu of options, where manufacturers can pick and choose.” Kicking the can down the road? France’s Ambassador Anne-Claire Amprou, co-chair of the talks, and WHO Director-General Dr Tedros at the conclusion of the Pandemic Agreement talks. Jean Karydakis, Counsellor in Brazil’s Mission in Geneva, acknowledged that the positions of the different groups – primarily developed countries versus developing countries – are fairly entrenched. “We won’t change other countries’ positions at this time,” he acknowledged. “The question now is whether we can find possible creative language, also bearing in mind that we will have a Conference of the Parties (COP) later on that will need to revisit and detail further what we cannot agree right now.” Karydakis also asserted that “90% of of the text is already agreed in the Pandemic Agreement, and the Pandemic Agreement was already adopted. “ But the PABS system was a contentious issue that evaded negotiators, who packaged it into an annex and kicked it down the road to new negotiations. This enabled the World Health Assembly to adopt the Pandemic Agreement last year, described by some observers as the Pandemic Agreement Lite precisely because it dodged the detail about PABS. Adopting a vague PABS annex and kicking further details down the road again – this time to the COP – might save face for multilateralism. But it simply delays the adoption of the Pandemic Agreement to yet another set of talks, leaving all member states vulnerable to public health emergencies in the meantime. Standard contracts? Developing countries want the annex to include a standard contract to govern access to biological material and digital sequencing, including benefit-sharing obligations. But Khokhar said that the IGWG Bureau and “other colleagues” have expressed that “a full standardised contract may not be the appropriate way”, as it is hard to predict what – if any – VTDs may be developed as a result. “Fair enough,” he said, adding that developing countries are prepared to explore the inclusion of a “basic contract” followed by a PABS contract, if a party has developed a medical countermeasure. “But what is their answer to this suggestion? Let’s have an open and a closed system. So, in this endeavour to try and find and create a multilateral system, we are actually going back to our national systems… What new system are we creating here? We’re creating nothing new?” For TWN, the lack of “contractually enforceable legal obligations for recipients of PABS materials and sequence information “will add to the legal uncertainty, as benefit-sharing will depend on the WHO concluding contracts with manufacturers. Namibian negotiator Taime Sylvester said that the funders of research in developing countries are “overwhelmingly high-income country governments and foundations”. They could “include PABS compliance as a condition of their grants,” said Sylvester, pointing to the example of the European Union’s Horizon Europe (2021–2027), its funding programme for research and innovation. This requires researchers to commit to Nagoya Protocol compliance, which mandates fair benefit-sharing from the use of genetic resources. Prospects for agreement Norwegian Health Counsellor Eirik Rodseth Bakka acknowledged that there are “significant outstanding issues, and I think as a collective, we do need to see significant progress next week”. However, he stressed that member states have the opportunity to “correct some of those inequities from the COVID-19 pandemic,” especially early access to vaccines for low- countries and lower-middle-income countries, and enabling “to the extent possible that there is more technology transfer and access to access to manufacturing capacity.” Karydakis expressed hope that “we will get this by May”, adding that talks may need to continue alongside the World Health Assembly in late May, the deadline for the annex. He also joked that night sessions were necessary to get people tired and hungry and “only able to leave the room when the deal is reached.” Sylvester said that Namibia believes that “a fair, functional, legally grounded PABS system” is possible and will assist both the global south and the global north need this functional system to succeed. So we we believe it. We believe that it can happen which is above and beyond, or we’re not asking any country to stand to a higher standard. We’re asking the same standards. Malaysia’s Hamza described the PABS system as “the litmus test for equity”. “We will have to see whether states will come in next week and design a PABS system that would actually make an improvement in the current status quo.When the Group for Equity gets together, the first thing we will assess is whether what we have agreed on, each paragraph, is really delivering equity.” Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
‘A String of Erratic Decisions’: National Science Foundation Advisory Board is Abruptly Dismissed 28/04/2026 Sophia Samantaroy The National Science Foundation spends its $9 billion budget on a range of scientific research, like quantum computing and material sciences. The White House has fired all 24 members of the National Science Board (NSB), the group that advises the National Science Foundation (NSF), in what some observers described as another example of the Trump Administration’s ‘blunt force approach’ to reshaping the nation’s science-based institutions. As of Monday evening, the White House still had not provided any explanation for President Donald Trump’s abrupt dismissal of the board members in an email on Friday. “On behalf of President Donald J. Trump, I’m writing to inform you that your position as a member of the National Science Board is terminated, effective immediately,” read the note. The move appeared to be part of a broader consolidation of civilian science-based advisory boards, inspired by DOGE-style cuts carried out by the White House Office of Management and Budget (OMB), Washington insiders said. And while the Department of Defense is ramping up its science, technology, and innovation advisory capacities, civilian research is getting the shorter end of the stick, critics said. “The question is: who’s helping steer basic research,” remarked one observer, who asked to remain anonymous. O’Neill to take reins of NSF Musical Chairs: Jim O’Neill (center) sworn in as Deputy HHS Secretary in June, 2025. In August, the venture capitalist took over the CDC and is now nominated to lead the National Science Foundation. The shakeup of the board, consisting of leading scientists and engineers from universities and industry, may also be designed to pave the way for Jim O’Neill, appointed by Trump as the new head of the NSF in February. O’Neill, a venture capitalist and tech investor, left his role as acting director of the Centers for Disease Control and Prevention (CDC) to take on the prestigious NSF post – an appointment that must be approved by Congress. The Senate has held off on scheduling O’Neill’s hearing, and he has faced criticism for being the only NSF nominee without scientific or engineering experience. It’s meanwhile unclear whether the board’s mass dismissal will be challenged in the courts. A federal judge last month ruled that HHS Secretary Robert F Kennedy Jr’s firing of the CDC’s entire Advisory Committee on Immunization Practices (ACIP) violated an Act meant to regulate advisory boards. Last year, Kennedy dismissed ACIP’s 17 members, appointing his own handpicked choices. The reconstituted board then changed the nation’s childhood vaccine schedule, reducing the number of recommended vaccines. Biggest shakeup in over 75 years The NSB, established alongside the NSF in 1950, advises Congress and the President on NSF research priorities. The NSF acts as the basic science and engineering counterpart to the National Institutes of Health (NIH). New NSB board members are appointed usually appointed by the White House administration for six-year terms, which means that there is a certain amount of political influence over individual appointments. But the mass dismissal of the entire board by a single administration is unprecedented. Other scientific organizations were quick to decry the move as undermining America’s scientific and research capabilities. “The dismissal of the National Science Board is the latest in a string of erratic decisions that are destabilizing not only the National Science Foundation, but all of American science,” said Dr Sudip Parikh, the chief executive officer of the American Association for the Advancement of Science (AAAS) and executive publisher of the Science family of journals. “Whatever the reasons, this action sets a precedent and implies that scientific priorities and policies will swing with the political whims of every administration.” Administration aims to slash NSF budget by more than half With an annual budget of nearly $10 billion, most NSB funding is channeled to universities for research on topics like artificial intelligence, quantum computing, physical sciences, and some environmental studies, such as polar research. The NSF has historically enjoyed bipartisan support as the leading funding mechanism for basic science and engineering research. Yet the administration’s current budget request for the upcoming year, if approved by Congress, would see a more than 50% reduction in NSF funding from the previous year – just $3.9 billion, compared to over $9.1 billion in 2025. “This is the latest stupid move made by a president who continues to harm science and American innovation,” said Representative Zoe Lofgren (D-19), the Democratic ranking member of the House Science, Space, and Technology committee, in a statement. “It unfortunately is no surprise a president who has attacked NSF from day one would seek to destroy the board that helps guide the Foundation. Will the president fill the NSB with MAGA loyalists who won’t stand up to him as he hands over our leadership in science to our adversaries?” Health Policy Watch reached out to the Committee Chair, Representative Brian Babin (R-36) for comment, but did not receive this by the time of publication. Leaders in academia, industry lend expertise The NSB’s statutes dictate that members must be “eminent in the fields of basic, medical or social sciences, engineering, agriculture, education, research management or public affairs.” The statutes also require members to be chosen based on a record of distinguished service and provide representation of the views of scientific and engineering leaders. Current members include deans and professors of universities across the country, as well as industry executives. Several members have served more than a decade each, after being reappointed by presidents across parties. “Typically consisting of stellar academic and industry leaders, the NSB has for decades guided NSF and informed scientific policies to deliver world-class science funded by NSF,” said Jane Lubchenco, a professor at Oregon State University and former deputy director for climate and environment at the White House Office of Science and Technology policy in a social media post. “Having served two terms on the NSB, across D[emocratic] and R[epublican] administrations, I am horrified by yet another powerful swing of the orange wrecking ball and attempts to demolish the scientific enterprise we need for a vibrant future.” Science innovation oriented towards defense An mRNA lab. A Defense Advanced Research Programs Agency (DARPA) initially funded research into the technology. While the NSF, along with NIH, and CDC have all been severely battered by deep budget cuts, leadership turmoil and layoffs, scientific investment in the DoD is expected to grow under the second Trump administration. Similarly, NASA’s budget has been reduced. The administration has prioritized human space flight over space science research. The administration has already consolidated two of the leading DoD science and technology advisory bodies into the Science, Technology, and Innovation Board (STIB). This board oversees a budget of $150 billion for science and technology innovation – 15 times larger than the NSF at its peak. However, this budget has also taken reductions in the latest budget request. The military has already used these funds to research six critical areas to national security: hypersonics, high energy lasers, artificial intelligence, quantum computing, biomanufacturing, and logistics and energy technologies. US is ‘abdicating’ as global leader in science, technology and discovery Along with the advisory boards embedded into the NIH, CDC and NSF, the federal government has a plethora of other acronym-heavy scientific advisory boards across various civilian agencies and departments. PCAST, the President’s Council of Advisors on Science and Technology, has the closest proximity to Trump. In the current administration, however, the council is mostly composed of high-level industry and tech leaders like Meta’s Mark Zuckerberg, and not academic scientists and engineers that make up the NSB. The net result, therefore, may be more driven by industry and private capital interests – rather than curiosity-driven basic science research. While every administration has its share of political appointees, the abrupt firing of the NSB board with little communication has the scientific community concerned. “If we want the United States to lead in science and technology and the benefits to accrue to the American people, we must have a vision, plan and resources guided by science, not politics,” said Sudip Parikh, CEO of the AAAS. “In the absence of clear communication from government leaders, this move, combined with other seemingly indiscriminate yet consequential decisions, reinforces the following message: America is abdicating its position as the global leader in science, technology and discovery. We cannot let this happen.” Image Credits: HHS Photo by Amy Rossetti, Rodger Bosch for MPP/WHO. Making Better Vaccine Choices in a Shifting Global Health Landscape 27/04/2026 Charlie Weller A baby gets a first dose of the measles, mumps and rubella (MMR) vaccine at a health center in Côte d’Ivoire. Global aid cuts have left countries struggling to meet childhood vaccine schedules. In an era of big global health budget cuts that often demand tough choices, identifying vaccine needs and priorities at national level is increasingly important. As we observe World Immunization Week, it’s time to recognize the pivotal role that National Immunization Technical Advisory Groups (NITAGs) can play in guiding effective, evidence-based decisions – alongside global guidance from the World Health Organization. From infancy to old age, vaccines are a life-saving tool. Over the past 50 years, vaccines have saved more than 150 million lives. They play a decisive role in keeping us safe from diseases through childhood, strengthening our immune responses in adulthood, and keeping us out of hospital in our older years. Immunisation currently prevents 3.5 million to 5 million deaths every year from diseases like tetanus, pertussis, influenza, and measles. Without vaccines, diseases consigned to the past could resurge in our present. Funding cuts and reduced resources are increasing barriers to vaccine research and development, as well as equitable access to immunisation – including the routine vaccination of young children in low- and middle-income countries. This reduction in support and resources is forcing organisations like the World Health Organization and Gavi, the Vaccine Alliance, to rethink how they operate. Vaccine decision-making is no longer about access alone; it’s about prioritisation under constraints. (Left to right columns). Deaths averted, years of life saved, and years of full health gained due to vaccination. From global guidance to national decision-making Many countries still rely heavily on vaccine recommendations made by the WHO through the Strategic Advisory Group of Experts on Immunization (SAGE). While being scientifically robust and relevant they do not always reflect the specific needs, challenges or health systems of individual countries. With global health funding undergoing dramatic reductions, countries and regions most affected by infectious diseases are facing difficult decisions about which diseases to prioritise and how best to procure and roll-out vaccines to maintain even fuller vaccination schedules. This greater emphasis on country-level decision-making is appropriate – countries affected by diseases are best placed to make decisions on how to tackle them. However, it takes time to build expertise and evidence, and responsibility is being decentralised faster than this capacity can be developed, with experts required to wear multiple hats. This is not merely a technical challenge, but a political and operational one. It requires a reshaping of power and accountability in global health structures. filling gaps in infrastructure to support more national and regional decision-making. SAGE Executive Secretary Joachim Hombach presents updates on WHO vaccine recommendations at a 2025 briefing. While such global guidance remains critical, a greater emphasis on country-level decision-making is also appropriate. Regional decisions need regional expertise Building regional sharing of expertise is now as critical as supply chains. This is where advisory groups such as the National Immunization Technical Advisory Groups (NITAGs), can play a pivotal role in guiding effective, evidence-based decisions. Each country’s NITAGs expertise differs, but their aim is the same – multidisciplinary independent experts assess whether international knowledge is applicable and relevant to local contexts, informing appropriate policy recommendations at a national level and bridging the gap between research and policy action. The impact of NITAGs can be felt quickly, allowing the introduction of specific vaccines that better suit the regional needs – whether it’s switching from one malaria vaccine to another in Nigeria, or the introduction of a Hepatitis B vaccine given at birth in Lesotho. For this model to work effectively, sustained funding is needed not just for research projects but to support policy-relevant expertise, enabling research to be translated into country-relevant recommendations. This is why Wellcome is investing in the African-led NITAG Support Hub, or NISH, which helps strengthen NITAGs across Africa. Through local evidence and support, and by sharing expertise and best practice via resource hubs, countries can be better prepared to navigate choices, including which of the increasingly robust array of lifesaving vaccines to prioritise, where, and how – all whilst aid and global health budgets are shrinking. Similarly, Gavi, The Vaccine Alliance has introduced ‘The Gavi Leap’ – a new operating model aiming to support country self-reliance to transition away from donor-led systems. Gavi Leap is increasing resources to help countries decide their own priorities, financing and delivery of vaccines with the long-term goal of immunisation sustainability. The intervention trade-offs A Kinshasa neighbourhood water point in DR Congo. Better WASH practices can complement cholera vaccination efforts in fighting the deadly disease. Amidst global instability, decision-makers increasingly need to balance the benefits of investing in one vaccine over another, as well as balancing the costs of vaccine procurement and distribution with spending on other interventions such as diagnostics and therapeutics, surveillance and health system strengthening. For example, while oral cholera vaccines alone protect individuals against the disease, and water, sanitation and hygiene (WASH) alone reduces the amount of bacteria in the environment, studies suggest that combining the oral cholera vaccine with improved household WASH leads to optimal protection. Oral cholera vaccination campaign in Democratic Republic of Congo, December 2023. There is a tricky balance to strike, taking into account factors such as available resources; behavioural attitudes to interventions; the benefits and risks of mass immunisation campaigns; and the needs of vulnerable, under-resourced communities. And any public health policies must take a long-term view, with the ability to adapt to changing circumstances – such as the emergence of new outbreaks, new pathogen variants, and new forms of disease resistance. Diverse expertise combined with awareness of local needs and barriers is essential to ensure vaccines are neither over-prioritised nor underused. Global health will, and must, be a global effort, and international guidance remains essential. But it cannot replace regional and national judgement and local knowledge of community needs and challenges. Investment in expertise means equitable vaccine policies With tightening global funding, choices between vaccines and other essential health interventions are unavoidable. Doing so without investment in more localised expertise is not. Investing in national and regional advisory capacity, knowledge-sharing and long-lasting expertise is not a luxury, it is the foundation of smarter, fairer vaccine decisions in an increasingly constrained world. Charlie Weller is the Head of Prevention in Wellcome’s Infectious Disease team. Since 2016, she has led the team to develop new and improved vaccines and antibodies – from managing the research and funding response to the Ebola epidemic of 2014-2015, to helping the co-founding of the Coalition for Epidemic Preparedness Innovations (CEPI), which is investing in new vaccine development that protects the world from epidemic and pandemic threats. Image Credits: UNICEF, Shattock A, Johnson H, Sim S et al.,The Lancet, May 2024, E. Fletcher/Health Policy Watch , Eduardo Soteras Jalil/ WHO, Esther Nsapu/Wellcome Trust. UN Deadlock and Iran War Oil Shocks Push 54 Nations to Chart Fossil Fuel Phase Out 27/04/2026 Stefan Anderson Governments, civil society and indigenous communities gather in Santa Marta Colombia to address the hurdle decades of UN climate summits have failed to clear: phasing out fossil fuels. More than 50 countries are gathering this week on Colombia’s Caribbean coast to launch a coalition for phasing out fossil fuels, as a third month of war in Iran exposes the costs of a global economy run on the oil, gas and coal driving the climate crisis that decades of deadlocked UN climate talks have failed to curb. No outcome text, funding or binding legal commitments are expected to come out of Santa Marta. Yet that the meeting exists at all – and is attended by several major fossil fuel powers including Australia, Canada, the United Kingdom, Nigeria and Norway – is a source of optimism for observers hoping it may be the start of a wind change in climate politics. The final tally of 54 states attending the first-of-its-kind conference is more than double the number of founding signatories who joined Colombia’s initiative as UN climate talks collapsed at COP30 in Belém last November. Combined, the coalition in Santa Marta represents around half of global GDP and 2.5 billion people, roughly a third of the global population. “The task for those attending is clear: not to debate whether to phase out fossil fuels but to determine how to do it – rapidly, fairly, and in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. “It has never been more urgent to leave behind oil, gas and coal than it is today.” Climate Change Is Here, And It’s Killing Millions Ministers and high-level delegations arrive on Tuesday and will negotiate through Wednesday evening. The primary goal, its host Colombia said, is “to launch an international coalition to jointly implement the transition away from fossil fuels.” “We need a multilateralism that is more deeply rooted in the people and not just in governments, biases or economic lobbying,” Colombian environment minister Irene Velez-Torres told AFP. “We need new alignments, new alliances. In that sense, we are a new power today,” she said, pointing to the global coalition in attendance. Fossil fuels are also driving a mounting public health catastrophe. Heat exposure now claims an estimated 546,000 lives annually, while air pollution from burning oil, gas and coal kills another 2.5 million people each year, according to the Lancet Countdown on health and climate change. “Fossil fuels are causing immediate harm,” said Jeni Miller, executive director of the Global Climate and Health Alliance, a consortium of more than 250 health organisations that submitted recommendations to the conference. “Phasing them out is not only about protecting the planet but also about saving lives in the near term, reducing strain on health systems, and creating greener, more just, and healthier societies.” The talks will aim to allow space for constructive negotiations among like-minded nations, unencumbered by the consensus-based UN system. Agreements at COPs require all 200 nations to sign off on the final text, a system which has allowed petrostates to block progress for decades. “The consensus methodology has resulted in a de facto veto against countries like Colombia that want more ambitious discussions on decisions, particularly related to fossil fuels,” Velez-Torres said. Who’s at the party? Boats sit along the Caribbean coastline of Santa Marta, Colombia, host city of the conference. Participants in Santa Marta include the European Union, the United Kingdom, small island developing states on the frontlines of sea level rise, several dozen developing nations, and COP31 co-hosts Turkey and Australia. Organisers said more than 2,600 civil society and indigenous community representatives are also in attendance in-person and online. Fossil fuel superpowers in the Gulf, the United States and Russia are not present. The world’s other biggest emitters including China, India, Iran and Japan, will also be absent. But unlike UN proceedings, which invite all member states by default, the tone struck by Colombia and the Netherlands is different: if you’re not going to help, don’t come. “We are not going to have boycotters or climate denialists at the table,” Vélez-Torres told the Guardian. “Whatever nations have not yet taken that decision, then this is not the space for them.” “Despite our differences, all participants agree on the need to prioritise science and to move forward, urgently and in a coordinated manner, toward phasing out the production and consumption of natural gas, coal, and oil,” she added in a statement shared by the summit presidency. The United States, for example, was not even invited. The Trump administration declined to send any delegation to COP30 in November — the first US absence from a UN climate summit since talks began in 1993 — and exited the Paris Climate Accord for a second time after President Donald Trump, who denies climate change, returned to office. “The president has been clear that the United States will not participate in the bogus climate agenda,” Taylor Rogers, a White House spokeswoman, said in a statement to the New York Times. Green momentum Delegates from the 24 founding nations of the fossil fuel phase-out conference initiative celebrate at COP30 in Belém, Brazil. As the US-Israeli war on Iran enters its third month with no clear end in sight, its shockwaves have caused the largest energy crisis in history – one that International Energy Agency chief Fatih Birol recently described as “worse than those of 1973, 1979, and 2022 combined.” It is the second major war-driven oil price shock in less than five years, after Russia’s invasion of Ukraine, and the crisis third since COVID-19 shut the global economy in 2019. That cascade of global crises is reshaping how COP negotiators are approaching this year’s summit. “No one has said this crisis is a reminder that we need to be more reliant on fossil fuels,” said Chris Bowen, Australia’s climate minister and lead negotiator for COP31, in his first interview in the role with the Guardian. “There’s a real appetite to emphasise reliability and energy sovereignty this year, and I think that does open up more opportunities for COP31.” The new war makes Colombia’s conference notably prescient, demonstrating the stability renewables could offer energy systems insulated from oil shocks. Wind gusts and sun rays – unlike roughly 20% of the world’s oil, gas and fertilizer – cannot be blocked in the Strait of Hormuz. “Sunlight travels 93 million miles to reach the earth,” environmentalist Bill McKibben wrote in a recent analysis. “None of them through the Strait of Hormuz.” Green momentum is visible around the world. Amid the Iran war, China smashed its previous solar technology export record by 50% in March, with the largest growth in Asian and African countries most reliant on Middle East fossil fuels, according to the energy think tank Ember. Last year, electricity from low-carbon sources overtook coal for the first time, and solar power generation rose 33% in 2025 as fossil fuel generation remained flat, Ember found. “Fossil shocks are boosting the solar surge,” said Euan Graham, a lead analyst for the Ember report. “Solar has already become the engine of the global economy, and now the current fossil fuel price shocks are taking it up a gear.” Some analysts have suggested developing nations may turn to home-produced coal to offset the shock, but solar is simply more competitive on cost and growth in the long- and short-term, Birol said. “COPs are unlikely now to be Paris or Copenhagen — outstanding successes or heartbreaking failures,” Bowen added. “COPs are more likely to be incremental progress. The question is how big that progress is.” Fossil fuel superpowers reap billions from crisis Russian oil companies are on course to make over $23 billion in additional profits this year due to the oil crisis, replenishing Putin’s wartime coffers as his invasion of Ukraine presses on. Yet even as renewables surge, windfall profits from the oil crisis continue to flow into the coffers of nations pivotal to blocking UN climate agreements. Russia, the United States and Saudi Arabia stand to gain the most: billions in new funding for Vladimir Putin’s war chest amid a grinding war in Ukraine, $60 billion in projected windfall profits for US oil and gas, and soaring values for state-owned oil giant Saudi Aramco despite major damage to its infrastructure in the war. A climate-forward shift from this axis of obstruction at COP31 — its strategy now vindicated by the crisis — is unlikely. The world’s top 100 oil and gas companies have earned an additional $30 million in profits per hour since the Iran war began. The oil and gas industry has made around $1 trillion in annual profits for over five decades, making it history’s most profitable industry. The same constellation of fossil fuel nations derailed hopes for a legally binding plastics treaty in August. With energy demand for fossil fuels falling, the industry is increasingly rerouting oil and gas into plastic and petrochemicals, making production limits in any treaty an existential threat. As coffers at ExxonMobil, Saudi Aramco and Rosneft fill, the World Food Programme estimates 45 million people will be pushed into hunger as a result of the oil and fertilizer crisis, with the toll potentially rising to record levels. Out of the ashes of Bélem: a coalition of the willing? As leaders gather at #SantaMarta conference on Transitioning Away from Fossil Fuels, fossil fuel giants are set to make nearly $3,000 every second in 2026—$94B that could power 50M people in Africa with solar. This isn’t normal, and it’s certainly not fair.#MakeRichPollutersPay pic.twitter.com/3U7k6onGUl — Oxfam in Africa (@OxfaminAfrica) April 27, 2026 Colombia launched the initiative in the final hours of COP30 in Belém, Brazil, when standoffs between countries supporting more ambition, and those blocking it, sent the summit into freefall. Two weeks of intensive negotiations ended in no concrete financial or legal outcomes from the much-hyped meeting in the Amazon – whose gradual is an iconic symbol of climate change. The frustration from that collapse spurred Colombia to launch the last-minute call for a fossil fuel phase-out conference, which at the time drew just 24 signatures from the 200 nations present. With 54 countries attending this week, the shape of Colombia’s initiative recalls a similar coalition that took years to build during negotiations for a legally binding plastic pollution treaty. That alliance, the High Ambition Coalition, had 20 founding members when talks opened in Paris in 2022. By the final round in Geneva in August, its then 75 members had rallied some 120 nations behind core binding provisions, including phasing out harmful chemicals from plastic production. That treaty ultimately fell short — blocked by the same axis of obstruction, this time led by Saudi Arabia and flanked by the US, Russia and Iran — but the negotiations produced real movement in global cooperation and national policymaking. Campaigners are aiming for the the same arc of momentum to be played in the fossil fuels arena now but more successfully. The big prize would be a treaty modelled on what the plastics coalition tried, but failed, to build, this time aimed at production limits on oil, gas and coal. “Santa Marta must support a coalition of the doers to recognise and remove legal barriers to halt oil and gas expansion — particularly offshore — and to pursue effective international cooperation on fossil fuel phase-out, through the future negotiation of a Fossil Fuel Treaty,” Reisch said. “Phasing out fossil fuels is not just a scientific necessity and a legal obligation, it’s also a critical opportunity to break free from a destructive system.” Image Credits: Ben Wicks, Yves Alarie. Developed Countries Propose ‘Hybrid’ Model Ahead of Pandemic Agreement Talks 26/04/2026 Kerry Cullinan IGWG negotiators (clockwise from top L): Nurhafiza Hamza (Malaysia), moderator Guilherme Faviero (AIDS Health Foundation), Jean Karydakis (Brazil), Taime Sylvester (Namibia), Eirik Rodseth Bakka (Norway) and Adeel Mumtaz Khokhar (Pakistan). Yet another negotiating session on the outstanding annex of the Pandemic Agreement begins at the World Health Organization’s (WHO) headquarters on Monday (27 April) – and developed nations have presented a “hybrid” solution in an attempt to find consensus. The “hybrid” proposal consists of a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. Adeel Mumtaz Khokhar, First Secretary to the Permanent Mission of Pakistan in Geneva, confirmed that a “hybrid” proposal had been presented to developing countries by some developed countries, but declined to name them. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The outstanding annex will set out terms for a pathogen access and benefit-sharing (PABS) system that ensures all countries have access to countermeasures to combat a pandemic or public health emergency of international concern (PHEIC) – unlike during COVID-19 when rich countries hoarded scarce vaccines. “We have been hearing rumours about this hybrid system for the past two IGWG [Intergovernmental Working Group] meetings, and finally, some developed country negotiator took pity on us and presented it,” Khokhar told a high-level webinar hosted by the University of Miami’s Public Health Policy Lab and AIDS Healthcare Foundation (AHF) last week. The proposal envisages two categories for biological material, Khokhar explained. To access one category, countries and manufacturers will “have to follow certain terms and conditions”, and these will be included in the PABS system. No terms or conditions apply to the other category of material, including benefit-sharing obligations. However, Third World Network (TWN), a civil society alliance tracking the negotiations, says that the hybrid system proposed by developed countries also envisages a split between information sharing and benefits. “Developed countries expect developing countries to share pathogen samples and sequence information freely, while deferring benefit-sharing to future negotiations between WHO and pharmaceutical manufacturers,” writes TWN in a recent brief. Maintains the status quo For Khokhar, the hybrid proposal “is essentially the status quo” as it allows parties to “share the way they want to share”. “So I’m not sure how fundamentally the needle is moved by this proposal. All I can understand from this proposal is that they want to retain and preserve the status quo, which, from a developing country negotiations perspective, is a disappointment.” Nurhafiza Hamza, Minister Counsellor for Health at Malaysia’s Permanent Mission to Geneva, explained that developing countries want “a set of mandatory benefit-sharing that is acceptable to different categories of users of the PABS system” – member states and pharmaceutical companies – during health emergencies. “If manufacturers have VTDs during a PHEIC or pandemic emergency, they should share,” said Hamza. “It is important to get some mandatory benefit sharing and not a menu of options, where manufacturers can pick and choose.” Kicking the can down the road? France’s Ambassador Anne-Claire Amprou, co-chair of the talks, and WHO Director-General Dr Tedros at the conclusion of the Pandemic Agreement talks. Jean Karydakis, Counsellor in Brazil’s Mission in Geneva, acknowledged that the positions of the different groups – primarily developed countries versus developing countries – are fairly entrenched. “We won’t change other countries’ positions at this time,” he acknowledged. “The question now is whether we can find possible creative language, also bearing in mind that we will have a Conference of the Parties (COP) later on that will need to revisit and detail further what we cannot agree right now.” Karydakis also asserted that “90% of of the text is already agreed in the Pandemic Agreement, and the Pandemic Agreement was already adopted. “ But the PABS system was a contentious issue that evaded negotiators, who packaged it into an annex and kicked it down the road to new negotiations. This enabled the World Health Assembly to adopt the Pandemic Agreement last year, described by some observers as the Pandemic Agreement Lite precisely because it dodged the detail about PABS. Adopting a vague PABS annex and kicking further details down the road again – this time to the COP – might save face for multilateralism. But it simply delays the adoption of the Pandemic Agreement to yet another set of talks, leaving all member states vulnerable to public health emergencies in the meantime. Standard contracts? Developing countries want the annex to include a standard contract to govern access to biological material and digital sequencing, including benefit-sharing obligations. But Khokhar said that the IGWG Bureau and “other colleagues” have expressed that “a full standardised contract may not be the appropriate way”, as it is hard to predict what – if any – VTDs may be developed as a result. “Fair enough,” he said, adding that developing countries are prepared to explore the inclusion of a “basic contract” followed by a PABS contract, if a party has developed a medical countermeasure. “But what is their answer to this suggestion? Let’s have an open and a closed system. So, in this endeavour to try and find and create a multilateral system, we are actually going back to our national systems… What new system are we creating here? We’re creating nothing new?” For TWN, the lack of “contractually enforceable legal obligations for recipients of PABS materials and sequence information “will add to the legal uncertainty, as benefit-sharing will depend on the WHO concluding contracts with manufacturers. Namibian negotiator Taime Sylvester said that the funders of research in developing countries are “overwhelmingly high-income country governments and foundations”. They could “include PABS compliance as a condition of their grants,” said Sylvester, pointing to the example of the European Union’s Horizon Europe (2021–2027), its funding programme for research and innovation. This requires researchers to commit to Nagoya Protocol compliance, which mandates fair benefit-sharing from the use of genetic resources. Prospects for agreement Norwegian Health Counsellor Eirik Rodseth Bakka acknowledged that there are “significant outstanding issues, and I think as a collective, we do need to see significant progress next week”. However, he stressed that member states have the opportunity to “correct some of those inequities from the COVID-19 pandemic,” especially early access to vaccines for low- countries and lower-middle-income countries, and enabling “to the extent possible that there is more technology transfer and access to access to manufacturing capacity.” Karydakis expressed hope that “we will get this by May”, adding that talks may need to continue alongside the World Health Assembly in late May, the deadline for the annex. He also joked that night sessions were necessary to get people tired and hungry and “only able to leave the room when the deal is reached.” Sylvester said that Namibia believes that “a fair, functional, legally grounded PABS system” is possible and will assist both the global south and the global north need this functional system to succeed. So we we believe it. We believe that it can happen which is above and beyond, or we’re not asking any country to stand to a higher standard. We’re asking the same standards. Malaysia’s Hamza described the PABS system as “the litmus test for equity”. “We will have to see whether states will come in next week and design a PABS system that would actually make an improvement in the current status quo.When the Group for Equity gets together, the first thing we will assess is whether what we have agreed on, each paragraph, is really delivering equity.” Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Making Better Vaccine Choices in a Shifting Global Health Landscape 27/04/2026 Charlie Weller A baby gets a first dose of the measles, mumps and rubella (MMR) vaccine at a health center in Côte d’Ivoire. Global aid cuts have left countries struggling to meet childhood vaccine schedules. In an era of big global health budget cuts that often demand tough choices, identifying vaccine needs and priorities at national level is increasingly important. As we observe World Immunization Week, it’s time to recognize the pivotal role that National Immunization Technical Advisory Groups (NITAGs) can play in guiding effective, evidence-based decisions – alongside global guidance from the World Health Organization. From infancy to old age, vaccines are a life-saving tool. Over the past 50 years, vaccines have saved more than 150 million lives. They play a decisive role in keeping us safe from diseases through childhood, strengthening our immune responses in adulthood, and keeping us out of hospital in our older years. Immunisation currently prevents 3.5 million to 5 million deaths every year from diseases like tetanus, pertussis, influenza, and measles. Without vaccines, diseases consigned to the past could resurge in our present. Funding cuts and reduced resources are increasing barriers to vaccine research and development, as well as equitable access to immunisation – including the routine vaccination of young children in low- and middle-income countries. This reduction in support and resources is forcing organisations like the World Health Organization and Gavi, the Vaccine Alliance, to rethink how they operate. Vaccine decision-making is no longer about access alone; it’s about prioritisation under constraints. (Left to right columns). Deaths averted, years of life saved, and years of full health gained due to vaccination. From global guidance to national decision-making Many countries still rely heavily on vaccine recommendations made by the WHO through the Strategic Advisory Group of Experts on Immunization (SAGE). While being scientifically robust and relevant they do not always reflect the specific needs, challenges or health systems of individual countries. With global health funding undergoing dramatic reductions, countries and regions most affected by infectious diseases are facing difficult decisions about which diseases to prioritise and how best to procure and roll-out vaccines to maintain even fuller vaccination schedules. This greater emphasis on country-level decision-making is appropriate – countries affected by diseases are best placed to make decisions on how to tackle them. However, it takes time to build expertise and evidence, and responsibility is being decentralised faster than this capacity can be developed, with experts required to wear multiple hats. This is not merely a technical challenge, but a political and operational one. It requires a reshaping of power and accountability in global health structures. filling gaps in infrastructure to support more national and regional decision-making. SAGE Executive Secretary Joachim Hombach presents updates on WHO vaccine recommendations at a 2025 briefing. While such global guidance remains critical, a greater emphasis on country-level decision-making is also appropriate. Regional decisions need regional expertise Building regional sharing of expertise is now as critical as supply chains. This is where advisory groups such as the National Immunization Technical Advisory Groups (NITAGs), can play a pivotal role in guiding effective, evidence-based decisions. Each country’s NITAGs expertise differs, but their aim is the same – multidisciplinary independent experts assess whether international knowledge is applicable and relevant to local contexts, informing appropriate policy recommendations at a national level and bridging the gap between research and policy action. The impact of NITAGs can be felt quickly, allowing the introduction of specific vaccines that better suit the regional needs – whether it’s switching from one malaria vaccine to another in Nigeria, or the introduction of a Hepatitis B vaccine given at birth in Lesotho. For this model to work effectively, sustained funding is needed not just for research projects but to support policy-relevant expertise, enabling research to be translated into country-relevant recommendations. This is why Wellcome is investing in the African-led NITAG Support Hub, or NISH, which helps strengthen NITAGs across Africa. Through local evidence and support, and by sharing expertise and best practice via resource hubs, countries can be better prepared to navigate choices, including which of the increasingly robust array of lifesaving vaccines to prioritise, where, and how – all whilst aid and global health budgets are shrinking. Similarly, Gavi, The Vaccine Alliance has introduced ‘The Gavi Leap’ – a new operating model aiming to support country self-reliance to transition away from donor-led systems. Gavi Leap is increasing resources to help countries decide their own priorities, financing and delivery of vaccines with the long-term goal of immunisation sustainability. The intervention trade-offs A Kinshasa neighbourhood water point in DR Congo. Better WASH practices can complement cholera vaccination efforts in fighting the deadly disease. Amidst global instability, decision-makers increasingly need to balance the benefits of investing in one vaccine over another, as well as balancing the costs of vaccine procurement and distribution with spending on other interventions such as diagnostics and therapeutics, surveillance and health system strengthening. For example, while oral cholera vaccines alone protect individuals against the disease, and water, sanitation and hygiene (WASH) alone reduces the amount of bacteria in the environment, studies suggest that combining the oral cholera vaccine with improved household WASH leads to optimal protection. Oral cholera vaccination campaign in Democratic Republic of Congo, December 2023. There is a tricky balance to strike, taking into account factors such as available resources; behavioural attitudes to interventions; the benefits and risks of mass immunisation campaigns; and the needs of vulnerable, under-resourced communities. And any public health policies must take a long-term view, with the ability to adapt to changing circumstances – such as the emergence of new outbreaks, new pathogen variants, and new forms of disease resistance. Diverse expertise combined with awareness of local needs and barriers is essential to ensure vaccines are neither over-prioritised nor underused. Global health will, and must, be a global effort, and international guidance remains essential. But it cannot replace regional and national judgement and local knowledge of community needs and challenges. Investment in expertise means equitable vaccine policies With tightening global funding, choices between vaccines and other essential health interventions are unavoidable. Doing so without investment in more localised expertise is not. Investing in national and regional advisory capacity, knowledge-sharing and long-lasting expertise is not a luxury, it is the foundation of smarter, fairer vaccine decisions in an increasingly constrained world. Charlie Weller is the Head of Prevention in Wellcome’s Infectious Disease team. Since 2016, she has led the team to develop new and improved vaccines and antibodies – from managing the research and funding response to the Ebola epidemic of 2014-2015, to helping the co-founding of the Coalition for Epidemic Preparedness Innovations (CEPI), which is investing in new vaccine development that protects the world from epidemic and pandemic threats. Image Credits: UNICEF, Shattock A, Johnson H, Sim S et al.,The Lancet, May 2024, E. Fletcher/Health Policy Watch , Eduardo Soteras Jalil/ WHO, Esther Nsapu/Wellcome Trust. UN Deadlock and Iran War Oil Shocks Push 54 Nations to Chart Fossil Fuel Phase Out 27/04/2026 Stefan Anderson Governments, civil society and indigenous communities gather in Santa Marta Colombia to address the hurdle decades of UN climate summits have failed to clear: phasing out fossil fuels. More than 50 countries are gathering this week on Colombia’s Caribbean coast to launch a coalition for phasing out fossil fuels, as a third month of war in Iran exposes the costs of a global economy run on the oil, gas and coal driving the climate crisis that decades of deadlocked UN climate talks have failed to curb. No outcome text, funding or binding legal commitments are expected to come out of Santa Marta. Yet that the meeting exists at all – and is attended by several major fossil fuel powers including Australia, Canada, the United Kingdom, Nigeria and Norway – is a source of optimism for observers hoping it may be the start of a wind change in climate politics. The final tally of 54 states attending the first-of-its-kind conference is more than double the number of founding signatories who joined Colombia’s initiative as UN climate talks collapsed at COP30 in Belém last November. Combined, the coalition in Santa Marta represents around half of global GDP and 2.5 billion people, roughly a third of the global population. “The task for those attending is clear: not to debate whether to phase out fossil fuels but to determine how to do it – rapidly, fairly, and in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. “It has never been more urgent to leave behind oil, gas and coal than it is today.” Climate Change Is Here, And It’s Killing Millions Ministers and high-level delegations arrive on Tuesday and will negotiate through Wednesday evening. The primary goal, its host Colombia said, is “to launch an international coalition to jointly implement the transition away from fossil fuels.” “We need a multilateralism that is more deeply rooted in the people and not just in governments, biases or economic lobbying,” Colombian environment minister Irene Velez-Torres told AFP. “We need new alignments, new alliances. In that sense, we are a new power today,” she said, pointing to the global coalition in attendance. Fossil fuels are also driving a mounting public health catastrophe. Heat exposure now claims an estimated 546,000 lives annually, while air pollution from burning oil, gas and coal kills another 2.5 million people each year, according to the Lancet Countdown on health and climate change. “Fossil fuels are causing immediate harm,” said Jeni Miller, executive director of the Global Climate and Health Alliance, a consortium of more than 250 health organisations that submitted recommendations to the conference. “Phasing them out is not only about protecting the planet but also about saving lives in the near term, reducing strain on health systems, and creating greener, more just, and healthier societies.” The talks will aim to allow space for constructive negotiations among like-minded nations, unencumbered by the consensus-based UN system. Agreements at COPs require all 200 nations to sign off on the final text, a system which has allowed petrostates to block progress for decades. “The consensus methodology has resulted in a de facto veto against countries like Colombia that want more ambitious discussions on decisions, particularly related to fossil fuels,” Velez-Torres said. Who’s at the party? Boats sit along the Caribbean coastline of Santa Marta, Colombia, host city of the conference. Participants in Santa Marta include the European Union, the United Kingdom, small island developing states on the frontlines of sea level rise, several dozen developing nations, and COP31 co-hosts Turkey and Australia. Organisers said more than 2,600 civil society and indigenous community representatives are also in attendance in-person and online. Fossil fuel superpowers in the Gulf, the United States and Russia are not present. The world’s other biggest emitters including China, India, Iran and Japan, will also be absent. But unlike UN proceedings, which invite all member states by default, the tone struck by Colombia and the Netherlands is different: if you’re not going to help, don’t come. “We are not going to have boycotters or climate denialists at the table,” Vélez-Torres told the Guardian. “Whatever nations have not yet taken that decision, then this is not the space for them.” “Despite our differences, all participants agree on the need to prioritise science and to move forward, urgently and in a coordinated manner, toward phasing out the production and consumption of natural gas, coal, and oil,” she added in a statement shared by the summit presidency. The United States, for example, was not even invited. The Trump administration declined to send any delegation to COP30 in November — the first US absence from a UN climate summit since talks began in 1993 — and exited the Paris Climate Accord for a second time after President Donald Trump, who denies climate change, returned to office. “The president has been clear that the United States will not participate in the bogus climate agenda,” Taylor Rogers, a White House spokeswoman, said in a statement to the New York Times. Green momentum Delegates from the 24 founding nations of the fossil fuel phase-out conference initiative celebrate at COP30 in Belém, Brazil. As the US-Israeli war on Iran enters its third month with no clear end in sight, its shockwaves have caused the largest energy crisis in history – one that International Energy Agency chief Fatih Birol recently described as “worse than those of 1973, 1979, and 2022 combined.” It is the second major war-driven oil price shock in less than five years, after Russia’s invasion of Ukraine, and the crisis third since COVID-19 shut the global economy in 2019. That cascade of global crises is reshaping how COP negotiators are approaching this year’s summit. “No one has said this crisis is a reminder that we need to be more reliant on fossil fuels,” said Chris Bowen, Australia’s climate minister and lead negotiator for COP31, in his first interview in the role with the Guardian. “There’s a real appetite to emphasise reliability and energy sovereignty this year, and I think that does open up more opportunities for COP31.” The new war makes Colombia’s conference notably prescient, demonstrating the stability renewables could offer energy systems insulated from oil shocks. Wind gusts and sun rays – unlike roughly 20% of the world’s oil, gas and fertilizer – cannot be blocked in the Strait of Hormuz. “Sunlight travels 93 million miles to reach the earth,” environmentalist Bill McKibben wrote in a recent analysis. “None of them through the Strait of Hormuz.” Green momentum is visible around the world. Amid the Iran war, China smashed its previous solar technology export record by 50% in March, with the largest growth in Asian and African countries most reliant on Middle East fossil fuels, according to the energy think tank Ember. Last year, electricity from low-carbon sources overtook coal for the first time, and solar power generation rose 33% in 2025 as fossil fuel generation remained flat, Ember found. “Fossil shocks are boosting the solar surge,” said Euan Graham, a lead analyst for the Ember report. “Solar has already become the engine of the global economy, and now the current fossil fuel price shocks are taking it up a gear.” Some analysts have suggested developing nations may turn to home-produced coal to offset the shock, but solar is simply more competitive on cost and growth in the long- and short-term, Birol said. “COPs are unlikely now to be Paris or Copenhagen — outstanding successes or heartbreaking failures,” Bowen added. “COPs are more likely to be incremental progress. The question is how big that progress is.” Fossil fuel superpowers reap billions from crisis Russian oil companies are on course to make over $23 billion in additional profits this year due to the oil crisis, replenishing Putin’s wartime coffers as his invasion of Ukraine presses on. Yet even as renewables surge, windfall profits from the oil crisis continue to flow into the coffers of nations pivotal to blocking UN climate agreements. Russia, the United States and Saudi Arabia stand to gain the most: billions in new funding for Vladimir Putin’s war chest amid a grinding war in Ukraine, $60 billion in projected windfall profits for US oil and gas, and soaring values for state-owned oil giant Saudi Aramco despite major damage to its infrastructure in the war. A climate-forward shift from this axis of obstruction at COP31 — its strategy now vindicated by the crisis — is unlikely. The world’s top 100 oil and gas companies have earned an additional $30 million in profits per hour since the Iran war began. The oil and gas industry has made around $1 trillion in annual profits for over five decades, making it history’s most profitable industry. The same constellation of fossil fuel nations derailed hopes for a legally binding plastics treaty in August. With energy demand for fossil fuels falling, the industry is increasingly rerouting oil and gas into plastic and petrochemicals, making production limits in any treaty an existential threat. As coffers at ExxonMobil, Saudi Aramco and Rosneft fill, the World Food Programme estimates 45 million people will be pushed into hunger as a result of the oil and fertilizer crisis, with the toll potentially rising to record levels. Out of the ashes of Bélem: a coalition of the willing? As leaders gather at #SantaMarta conference on Transitioning Away from Fossil Fuels, fossil fuel giants are set to make nearly $3,000 every second in 2026—$94B that could power 50M people in Africa with solar. This isn’t normal, and it’s certainly not fair.#MakeRichPollutersPay pic.twitter.com/3U7k6onGUl — Oxfam in Africa (@OxfaminAfrica) April 27, 2026 Colombia launched the initiative in the final hours of COP30 in Belém, Brazil, when standoffs between countries supporting more ambition, and those blocking it, sent the summit into freefall. Two weeks of intensive negotiations ended in no concrete financial or legal outcomes from the much-hyped meeting in the Amazon – whose gradual is an iconic symbol of climate change. The frustration from that collapse spurred Colombia to launch the last-minute call for a fossil fuel phase-out conference, which at the time drew just 24 signatures from the 200 nations present. With 54 countries attending this week, the shape of Colombia’s initiative recalls a similar coalition that took years to build during negotiations for a legally binding plastic pollution treaty. That alliance, the High Ambition Coalition, had 20 founding members when talks opened in Paris in 2022. By the final round in Geneva in August, its then 75 members had rallied some 120 nations behind core binding provisions, including phasing out harmful chemicals from plastic production. That treaty ultimately fell short — blocked by the same axis of obstruction, this time led by Saudi Arabia and flanked by the US, Russia and Iran — but the negotiations produced real movement in global cooperation and national policymaking. Campaigners are aiming for the the same arc of momentum to be played in the fossil fuels arena now but more successfully. The big prize would be a treaty modelled on what the plastics coalition tried, but failed, to build, this time aimed at production limits on oil, gas and coal. “Santa Marta must support a coalition of the doers to recognise and remove legal barriers to halt oil and gas expansion — particularly offshore — and to pursue effective international cooperation on fossil fuel phase-out, through the future negotiation of a Fossil Fuel Treaty,” Reisch said. “Phasing out fossil fuels is not just a scientific necessity and a legal obligation, it’s also a critical opportunity to break free from a destructive system.” Image Credits: Ben Wicks, Yves Alarie. Developed Countries Propose ‘Hybrid’ Model Ahead of Pandemic Agreement Talks 26/04/2026 Kerry Cullinan IGWG negotiators (clockwise from top L): Nurhafiza Hamza (Malaysia), moderator Guilherme Faviero (AIDS Health Foundation), Jean Karydakis (Brazil), Taime Sylvester (Namibia), Eirik Rodseth Bakka (Norway) and Adeel Mumtaz Khokhar (Pakistan). Yet another negotiating session on the outstanding annex of the Pandemic Agreement begins at the World Health Organization’s (WHO) headquarters on Monday (27 April) – and developed nations have presented a “hybrid” solution in an attempt to find consensus. The “hybrid” proposal consists of a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. Adeel Mumtaz Khokhar, First Secretary to the Permanent Mission of Pakistan in Geneva, confirmed that a “hybrid” proposal had been presented to developing countries by some developed countries, but declined to name them. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The outstanding annex will set out terms for a pathogen access and benefit-sharing (PABS) system that ensures all countries have access to countermeasures to combat a pandemic or public health emergency of international concern (PHEIC) – unlike during COVID-19 when rich countries hoarded scarce vaccines. “We have been hearing rumours about this hybrid system for the past two IGWG [Intergovernmental Working Group] meetings, and finally, some developed country negotiator took pity on us and presented it,” Khokhar told a high-level webinar hosted by the University of Miami’s Public Health Policy Lab and AIDS Healthcare Foundation (AHF) last week. The proposal envisages two categories for biological material, Khokhar explained. To access one category, countries and manufacturers will “have to follow certain terms and conditions”, and these will be included in the PABS system. No terms or conditions apply to the other category of material, including benefit-sharing obligations. However, Third World Network (TWN), a civil society alliance tracking the negotiations, says that the hybrid system proposed by developed countries also envisages a split between information sharing and benefits. “Developed countries expect developing countries to share pathogen samples and sequence information freely, while deferring benefit-sharing to future negotiations between WHO and pharmaceutical manufacturers,” writes TWN in a recent brief. Maintains the status quo For Khokhar, the hybrid proposal “is essentially the status quo” as it allows parties to “share the way they want to share”. “So I’m not sure how fundamentally the needle is moved by this proposal. All I can understand from this proposal is that they want to retain and preserve the status quo, which, from a developing country negotiations perspective, is a disappointment.” Nurhafiza Hamza, Minister Counsellor for Health at Malaysia’s Permanent Mission to Geneva, explained that developing countries want “a set of mandatory benefit-sharing that is acceptable to different categories of users of the PABS system” – member states and pharmaceutical companies – during health emergencies. “If manufacturers have VTDs during a PHEIC or pandemic emergency, they should share,” said Hamza. “It is important to get some mandatory benefit sharing and not a menu of options, where manufacturers can pick and choose.” Kicking the can down the road? France’s Ambassador Anne-Claire Amprou, co-chair of the talks, and WHO Director-General Dr Tedros at the conclusion of the Pandemic Agreement talks. Jean Karydakis, Counsellor in Brazil’s Mission in Geneva, acknowledged that the positions of the different groups – primarily developed countries versus developing countries – are fairly entrenched. “We won’t change other countries’ positions at this time,” he acknowledged. “The question now is whether we can find possible creative language, also bearing in mind that we will have a Conference of the Parties (COP) later on that will need to revisit and detail further what we cannot agree right now.” Karydakis also asserted that “90% of of the text is already agreed in the Pandemic Agreement, and the Pandemic Agreement was already adopted. “ But the PABS system was a contentious issue that evaded negotiators, who packaged it into an annex and kicked it down the road to new negotiations. This enabled the World Health Assembly to adopt the Pandemic Agreement last year, described by some observers as the Pandemic Agreement Lite precisely because it dodged the detail about PABS. Adopting a vague PABS annex and kicking further details down the road again – this time to the COP – might save face for multilateralism. But it simply delays the adoption of the Pandemic Agreement to yet another set of talks, leaving all member states vulnerable to public health emergencies in the meantime. Standard contracts? Developing countries want the annex to include a standard contract to govern access to biological material and digital sequencing, including benefit-sharing obligations. But Khokhar said that the IGWG Bureau and “other colleagues” have expressed that “a full standardised contract may not be the appropriate way”, as it is hard to predict what – if any – VTDs may be developed as a result. “Fair enough,” he said, adding that developing countries are prepared to explore the inclusion of a “basic contract” followed by a PABS contract, if a party has developed a medical countermeasure. “But what is their answer to this suggestion? Let’s have an open and a closed system. So, in this endeavour to try and find and create a multilateral system, we are actually going back to our national systems… What new system are we creating here? We’re creating nothing new?” For TWN, the lack of “contractually enforceable legal obligations for recipients of PABS materials and sequence information “will add to the legal uncertainty, as benefit-sharing will depend on the WHO concluding contracts with manufacturers. Namibian negotiator Taime Sylvester said that the funders of research in developing countries are “overwhelmingly high-income country governments and foundations”. They could “include PABS compliance as a condition of their grants,” said Sylvester, pointing to the example of the European Union’s Horizon Europe (2021–2027), its funding programme for research and innovation. This requires researchers to commit to Nagoya Protocol compliance, which mandates fair benefit-sharing from the use of genetic resources. Prospects for agreement Norwegian Health Counsellor Eirik Rodseth Bakka acknowledged that there are “significant outstanding issues, and I think as a collective, we do need to see significant progress next week”. However, he stressed that member states have the opportunity to “correct some of those inequities from the COVID-19 pandemic,” especially early access to vaccines for low- countries and lower-middle-income countries, and enabling “to the extent possible that there is more technology transfer and access to access to manufacturing capacity.” Karydakis expressed hope that “we will get this by May”, adding that talks may need to continue alongside the World Health Assembly in late May, the deadline for the annex. He also joked that night sessions were necessary to get people tired and hungry and “only able to leave the room when the deal is reached.” Sylvester said that Namibia believes that “a fair, functional, legally grounded PABS system” is possible and will assist both the global south and the global north need this functional system to succeed. So we we believe it. We believe that it can happen which is above and beyond, or we’re not asking any country to stand to a higher standard. We’re asking the same standards. Malaysia’s Hamza described the PABS system as “the litmus test for equity”. “We will have to see whether states will come in next week and design a PABS system that would actually make an improvement in the current status quo.When the Group for Equity gets together, the first thing we will assess is whether what we have agreed on, each paragraph, is really delivering equity.” Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
UN Deadlock and Iran War Oil Shocks Push 54 Nations to Chart Fossil Fuel Phase Out 27/04/2026 Stefan Anderson Governments, civil society and indigenous communities gather in Santa Marta Colombia to address the hurdle decades of UN climate summits have failed to clear: phasing out fossil fuels. More than 50 countries are gathering this week on Colombia’s Caribbean coast to launch a coalition for phasing out fossil fuels, as a third month of war in Iran exposes the costs of a global economy run on the oil, gas and coal driving the climate crisis that decades of deadlocked UN climate talks have failed to curb. No outcome text, funding or binding legal commitments are expected to come out of Santa Marta. Yet that the meeting exists at all – and is attended by several major fossil fuel powers including Australia, Canada, the United Kingdom, Nigeria and Norway – is a source of optimism for observers hoping it may be the start of a wind change in climate politics. The final tally of 54 states attending the first-of-its-kind conference is more than double the number of founding signatories who joined Colombia’s initiative as UN climate talks collapsed at COP30 in Belém last November. Combined, the coalition in Santa Marta represents around half of global GDP and 2.5 billion people, roughly a third of the global population. “The task for those attending is clear: not to debate whether to phase out fossil fuels but to determine how to do it – rapidly, fairly, and in line with science and the law,” said Nikki Reisch, director of climate and energy at the Centre for International Environmental Law. “It has never been more urgent to leave behind oil, gas and coal than it is today.” Climate Change Is Here, And It’s Killing Millions Ministers and high-level delegations arrive on Tuesday and will negotiate through Wednesday evening. The primary goal, its host Colombia said, is “to launch an international coalition to jointly implement the transition away from fossil fuels.” “We need a multilateralism that is more deeply rooted in the people and not just in governments, biases or economic lobbying,” Colombian environment minister Irene Velez-Torres told AFP. “We need new alignments, new alliances. In that sense, we are a new power today,” she said, pointing to the global coalition in attendance. Fossil fuels are also driving a mounting public health catastrophe. Heat exposure now claims an estimated 546,000 lives annually, while air pollution from burning oil, gas and coal kills another 2.5 million people each year, according to the Lancet Countdown on health and climate change. “Fossil fuels are causing immediate harm,” said Jeni Miller, executive director of the Global Climate and Health Alliance, a consortium of more than 250 health organisations that submitted recommendations to the conference. “Phasing them out is not only about protecting the planet but also about saving lives in the near term, reducing strain on health systems, and creating greener, more just, and healthier societies.” The talks will aim to allow space for constructive negotiations among like-minded nations, unencumbered by the consensus-based UN system. Agreements at COPs require all 200 nations to sign off on the final text, a system which has allowed petrostates to block progress for decades. “The consensus methodology has resulted in a de facto veto against countries like Colombia that want more ambitious discussions on decisions, particularly related to fossil fuels,” Velez-Torres said. Who’s at the party? Boats sit along the Caribbean coastline of Santa Marta, Colombia, host city of the conference. Participants in Santa Marta include the European Union, the United Kingdom, small island developing states on the frontlines of sea level rise, several dozen developing nations, and COP31 co-hosts Turkey and Australia. Organisers said more than 2,600 civil society and indigenous community representatives are also in attendance in-person and online. Fossil fuel superpowers in the Gulf, the United States and Russia are not present. The world’s other biggest emitters including China, India, Iran and Japan, will also be absent. But unlike UN proceedings, which invite all member states by default, the tone struck by Colombia and the Netherlands is different: if you’re not going to help, don’t come. “We are not going to have boycotters or climate denialists at the table,” Vélez-Torres told the Guardian. “Whatever nations have not yet taken that decision, then this is not the space for them.” “Despite our differences, all participants agree on the need to prioritise science and to move forward, urgently and in a coordinated manner, toward phasing out the production and consumption of natural gas, coal, and oil,” she added in a statement shared by the summit presidency. The United States, for example, was not even invited. The Trump administration declined to send any delegation to COP30 in November — the first US absence from a UN climate summit since talks began in 1993 — and exited the Paris Climate Accord for a second time after President Donald Trump, who denies climate change, returned to office. “The president has been clear that the United States will not participate in the bogus climate agenda,” Taylor Rogers, a White House spokeswoman, said in a statement to the New York Times. Green momentum Delegates from the 24 founding nations of the fossil fuel phase-out conference initiative celebrate at COP30 in Belém, Brazil. As the US-Israeli war on Iran enters its third month with no clear end in sight, its shockwaves have caused the largest energy crisis in history – one that International Energy Agency chief Fatih Birol recently described as “worse than those of 1973, 1979, and 2022 combined.” It is the second major war-driven oil price shock in less than five years, after Russia’s invasion of Ukraine, and the crisis third since COVID-19 shut the global economy in 2019. That cascade of global crises is reshaping how COP negotiators are approaching this year’s summit. “No one has said this crisis is a reminder that we need to be more reliant on fossil fuels,” said Chris Bowen, Australia’s climate minister and lead negotiator for COP31, in his first interview in the role with the Guardian. “There’s a real appetite to emphasise reliability and energy sovereignty this year, and I think that does open up more opportunities for COP31.” The new war makes Colombia’s conference notably prescient, demonstrating the stability renewables could offer energy systems insulated from oil shocks. Wind gusts and sun rays – unlike roughly 20% of the world’s oil, gas and fertilizer – cannot be blocked in the Strait of Hormuz. “Sunlight travels 93 million miles to reach the earth,” environmentalist Bill McKibben wrote in a recent analysis. “None of them through the Strait of Hormuz.” Green momentum is visible around the world. Amid the Iran war, China smashed its previous solar technology export record by 50% in March, with the largest growth in Asian and African countries most reliant on Middle East fossil fuels, according to the energy think tank Ember. Last year, electricity from low-carbon sources overtook coal for the first time, and solar power generation rose 33% in 2025 as fossil fuel generation remained flat, Ember found. “Fossil shocks are boosting the solar surge,” said Euan Graham, a lead analyst for the Ember report. “Solar has already become the engine of the global economy, and now the current fossil fuel price shocks are taking it up a gear.” Some analysts have suggested developing nations may turn to home-produced coal to offset the shock, but solar is simply more competitive on cost and growth in the long- and short-term, Birol said. “COPs are unlikely now to be Paris or Copenhagen — outstanding successes or heartbreaking failures,” Bowen added. “COPs are more likely to be incremental progress. The question is how big that progress is.” Fossil fuel superpowers reap billions from crisis Russian oil companies are on course to make over $23 billion in additional profits this year due to the oil crisis, replenishing Putin’s wartime coffers as his invasion of Ukraine presses on. Yet even as renewables surge, windfall profits from the oil crisis continue to flow into the coffers of nations pivotal to blocking UN climate agreements. Russia, the United States and Saudi Arabia stand to gain the most: billions in new funding for Vladimir Putin’s war chest amid a grinding war in Ukraine, $60 billion in projected windfall profits for US oil and gas, and soaring values for state-owned oil giant Saudi Aramco despite major damage to its infrastructure in the war. A climate-forward shift from this axis of obstruction at COP31 — its strategy now vindicated by the crisis — is unlikely. The world’s top 100 oil and gas companies have earned an additional $30 million in profits per hour since the Iran war began. The oil and gas industry has made around $1 trillion in annual profits for over five decades, making it history’s most profitable industry. The same constellation of fossil fuel nations derailed hopes for a legally binding plastics treaty in August. With energy demand for fossil fuels falling, the industry is increasingly rerouting oil and gas into plastic and petrochemicals, making production limits in any treaty an existential threat. As coffers at ExxonMobil, Saudi Aramco and Rosneft fill, the World Food Programme estimates 45 million people will be pushed into hunger as a result of the oil and fertilizer crisis, with the toll potentially rising to record levels. Out of the ashes of Bélem: a coalition of the willing? As leaders gather at #SantaMarta conference on Transitioning Away from Fossil Fuels, fossil fuel giants are set to make nearly $3,000 every second in 2026—$94B that could power 50M people in Africa with solar. This isn’t normal, and it’s certainly not fair.#MakeRichPollutersPay pic.twitter.com/3U7k6onGUl — Oxfam in Africa (@OxfaminAfrica) April 27, 2026 Colombia launched the initiative in the final hours of COP30 in Belém, Brazil, when standoffs between countries supporting more ambition, and those blocking it, sent the summit into freefall. Two weeks of intensive negotiations ended in no concrete financial or legal outcomes from the much-hyped meeting in the Amazon – whose gradual is an iconic symbol of climate change. The frustration from that collapse spurred Colombia to launch the last-minute call for a fossil fuel phase-out conference, which at the time drew just 24 signatures from the 200 nations present. With 54 countries attending this week, the shape of Colombia’s initiative recalls a similar coalition that took years to build during negotiations for a legally binding plastic pollution treaty. That alliance, the High Ambition Coalition, had 20 founding members when talks opened in Paris in 2022. By the final round in Geneva in August, its then 75 members had rallied some 120 nations behind core binding provisions, including phasing out harmful chemicals from plastic production. That treaty ultimately fell short — blocked by the same axis of obstruction, this time led by Saudi Arabia and flanked by the US, Russia and Iran — but the negotiations produced real movement in global cooperation and national policymaking. Campaigners are aiming for the the same arc of momentum to be played in the fossil fuels arena now but more successfully. The big prize would be a treaty modelled on what the plastics coalition tried, but failed, to build, this time aimed at production limits on oil, gas and coal. “Santa Marta must support a coalition of the doers to recognise and remove legal barriers to halt oil and gas expansion — particularly offshore — and to pursue effective international cooperation on fossil fuel phase-out, through the future negotiation of a Fossil Fuel Treaty,” Reisch said. “Phasing out fossil fuels is not just a scientific necessity and a legal obligation, it’s also a critical opportunity to break free from a destructive system.” Image Credits: Ben Wicks, Yves Alarie. Developed Countries Propose ‘Hybrid’ Model Ahead of Pandemic Agreement Talks 26/04/2026 Kerry Cullinan IGWG negotiators (clockwise from top L): Nurhafiza Hamza (Malaysia), moderator Guilherme Faviero (AIDS Health Foundation), Jean Karydakis (Brazil), Taime Sylvester (Namibia), Eirik Rodseth Bakka (Norway) and Adeel Mumtaz Khokhar (Pakistan). Yet another negotiating session on the outstanding annex of the Pandemic Agreement begins at the World Health Organization’s (WHO) headquarters on Monday (27 April) – and developed nations have presented a “hybrid” solution in an attempt to find consensus. The “hybrid” proposal consists of a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. Adeel Mumtaz Khokhar, First Secretary to the Permanent Mission of Pakistan in Geneva, confirmed that a “hybrid” proposal had been presented to developing countries by some developed countries, but declined to name them. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The outstanding annex will set out terms for a pathogen access and benefit-sharing (PABS) system that ensures all countries have access to countermeasures to combat a pandemic or public health emergency of international concern (PHEIC) – unlike during COVID-19 when rich countries hoarded scarce vaccines. “We have been hearing rumours about this hybrid system for the past two IGWG [Intergovernmental Working Group] meetings, and finally, some developed country negotiator took pity on us and presented it,” Khokhar told a high-level webinar hosted by the University of Miami’s Public Health Policy Lab and AIDS Healthcare Foundation (AHF) last week. The proposal envisages two categories for biological material, Khokhar explained. To access one category, countries and manufacturers will “have to follow certain terms and conditions”, and these will be included in the PABS system. No terms or conditions apply to the other category of material, including benefit-sharing obligations. However, Third World Network (TWN), a civil society alliance tracking the negotiations, says that the hybrid system proposed by developed countries also envisages a split between information sharing and benefits. “Developed countries expect developing countries to share pathogen samples and sequence information freely, while deferring benefit-sharing to future negotiations between WHO and pharmaceutical manufacturers,” writes TWN in a recent brief. Maintains the status quo For Khokhar, the hybrid proposal “is essentially the status quo” as it allows parties to “share the way they want to share”. “So I’m not sure how fundamentally the needle is moved by this proposal. All I can understand from this proposal is that they want to retain and preserve the status quo, which, from a developing country negotiations perspective, is a disappointment.” Nurhafiza Hamza, Minister Counsellor for Health at Malaysia’s Permanent Mission to Geneva, explained that developing countries want “a set of mandatory benefit-sharing that is acceptable to different categories of users of the PABS system” – member states and pharmaceutical companies – during health emergencies. “If manufacturers have VTDs during a PHEIC or pandemic emergency, they should share,” said Hamza. “It is important to get some mandatory benefit sharing and not a menu of options, where manufacturers can pick and choose.” Kicking the can down the road? France’s Ambassador Anne-Claire Amprou, co-chair of the talks, and WHO Director-General Dr Tedros at the conclusion of the Pandemic Agreement talks. Jean Karydakis, Counsellor in Brazil’s Mission in Geneva, acknowledged that the positions of the different groups – primarily developed countries versus developing countries – are fairly entrenched. “We won’t change other countries’ positions at this time,” he acknowledged. “The question now is whether we can find possible creative language, also bearing in mind that we will have a Conference of the Parties (COP) later on that will need to revisit and detail further what we cannot agree right now.” Karydakis also asserted that “90% of of the text is already agreed in the Pandemic Agreement, and the Pandemic Agreement was already adopted. “ But the PABS system was a contentious issue that evaded negotiators, who packaged it into an annex and kicked it down the road to new negotiations. This enabled the World Health Assembly to adopt the Pandemic Agreement last year, described by some observers as the Pandemic Agreement Lite precisely because it dodged the detail about PABS. Adopting a vague PABS annex and kicking further details down the road again – this time to the COP – might save face for multilateralism. But it simply delays the adoption of the Pandemic Agreement to yet another set of talks, leaving all member states vulnerable to public health emergencies in the meantime. Standard contracts? Developing countries want the annex to include a standard contract to govern access to biological material and digital sequencing, including benefit-sharing obligations. But Khokhar said that the IGWG Bureau and “other colleagues” have expressed that “a full standardised contract may not be the appropriate way”, as it is hard to predict what – if any – VTDs may be developed as a result. “Fair enough,” he said, adding that developing countries are prepared to explore the inclusion of a “basic contract” followed by a PABS contract, if a party has developed a medical countermeasure. “But what is their answer to this suggestion? Let’s have an open and a closed system. So, in this endeavour to try and find and create a multilateral system, we are actually going back to our national systems… What new system are we creating here? We’re creating nothing new?” For TWN, the lack of “contractually enforceable legal obligations for recipients of PABS materials and sequence information “will add to the legal uncertainty, as benefit-sharing will depend on the WHO concluding contracts with manufacturers. Namibian negotiator Taime Sylvester said that the funders of research in developing countries are “overwhelmingly high-income country governments and foundations”. They could “include PABS compliance as a condition of their grants,” said Sylvester, pointing to the example of the European Union’s Horizon Europe (2021–2027), its funding programme for research and innovation. This requires researchers to commit to Nagoya Protocol compliance, which mandates fair benefit-sharing from the use of genetic resources. Prospects for agreement Norwegian Health Counsellor Eirik Rodseth Bakka acknowledged that there are “significant outstanding issues, and I think as a collective, we do need to see significant progress next week”. However, he stressed that member states have the opportunity to “correct some of those inequities from the COVID-19 pandemic,” especially early access to vaccines for low- countries and lower-middle-income countries, and enabling “to the extent possible that there is more technology transfer and access to access to manufacturing capacity.” Karydakis expressed hope that “we will get this by May”, adding that talks may need to continue alongside the World Health Assembly in late May, the deadline for the annex. He also joked that night sessions were necessary to get people tired and hungry and “only able to leave the room when the deal is reached.” Sylvester said that Namibia believes that “a fair, functional, legally grounded PABS system” is possible and will assist both the global south and the global north need this functional system to succeed. So we we believe it. We believe that it can happen which is above and beyond, or we’re not asking any country to stand to a higher standard. We’re asking the same standards. Malaysia’s Hamza described the PABS system as “the litmus test for equity”. “We will have to see whether states will come in next week and design a PABS system that would actually make an improvement in the current status quo.When the Group for Equity gets together, the first thing we will assess is whether what we have agreed on, each paragraph, is really delivering equity.” Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Developed Countries Propose ‘Hybrid’ Model Ahead of Pandemic Agreement Talks 26/04/2026 Kerry Cullinan IGWG negotiators (clockwise from top L): Nurhafiza Hamza (Malaysia), moderator Guilherme Faviero (AIDS Health Foundation), Jean Karydakis (Brazil), Taime Sylvester (Namibia), Eirik Rodseth Bakka (Norway) and Adeel Mumtaz Khokhar (Pakistan). Yet another negotiating session on the outstanding annex of the Pandemic Agreement begins at the World Health Organization’s (WHO) headquarters on Monday (27 April) – and developed nations have presented a “hybrid” solution in an attempt to find consensus. The “hybrid” proposal consists of a mix of mandatory and voluntary measures for sharing pathogen information and any benefits that flow from this information. Adeel Mumtaz Khokhar, First Secretary to the Permanent Mission of Pakistan in Geneva, confirmed that a “hybrid” proposal had been presented to developing countries by some developed countries, but declined to name them. WHO member states are negotiating how to share both information about dangerous pathogens and some of the “benefits” that manufacturers may develop from that information – namely, vaccines, therapeutics and diagnostics (VTDs). The outstanding annex will set out terms for a pathogen access and benefit-sharing (PABS) system that ensures all countries have access to countermeasures to combat a pandemic or public health emergency of international concern (PHEIC) – unlike during COVID-19 when rich countries hoarded scarce vaccines. “We have been hearing rumours about this hybrid system for the past two IGWG [Intergovernmental Working Group] meetings, and finally, some developed country negotiator took pity on us and presented it,” Khokhar told a high-level webinar hosted by the University of Miami’s Public Health Policy Lab and AIDS Healthcare Foundation (AHF) last week. The proposal envisages two categories for biological material, Khokhar explained. To access one category, countries and manufacturers will “have to follow certain terms and conditions”, and these will be included in the PABS system. No terms or conditions apply to the other category of material, including benefit-sharing obligations. However, Third World Network (TWN), a civil society alliance tracking the negotiations, says that the hybrid system proposed by developed countries also envisages a split between information sharing and benefits. “Developed countries expect developing countries to share pathogen samples and sequence information freely, while deferring benefit-sharing to future negotiations between WHO and pharmaceutical manufacturers,” writes TWN in a recent brief. Maintains the status quo For Khokhar, the hybrid proposal “is essentially the status quo” as it allows parties to “share the way they want to share”. “So I’m not sure how fundamentally the needle is moved by this proposal. All I can understand from this proposal is that they want to retain and preserve the status quo, which, from a developing country negotiations perspective, is a disappointment.” Nurhafiza Hamza, Minister Counsellor for Health at Malaysia’s Permanent Mission to Geneva, explained that developing countries want “a set of mandatory benefit-sharing that is acceptable to different categories of users of the PABS system” – member states and pharmaceutical companies – during health emergencies. “If manufacturers have VTDs during a PHEIC or pandemic emergency, they should share,” said Hamza. “It is important to get some mandatory benefit sharing and not a menu of options, where manufacturers can pick and choose.” Kicking the can down the road? France’s Ambassador Anne-Claire Amprou, co-chair of the talks, and WHO Director-General Dr Tedros at the conclusion of the Pandemic Agreement talks. Jean Karydakis, Counsellor in Brazil’s Mission in Geneva, acknowledged that the positions of the different groups – primarily developed countries versus developing countries – are fairly entrenched. “We won’t change other countries’ positions at this time,” he acknowledged. “The question now is whether we can find possible creative language, also bearing in mind that we will have a Conference of the Parties (COP) later on that will need to revisit and detail further what we cannot agree right now.” Karydakis also asserted that “90% of of the text is already agreed in the Pandemic Agreement, and the Pandemic Agreement was already adopted. “ But the PABS system was a contentious issue that evaded negotiators, who packaged it into an annex and kicked it down the road to new negotiations. This enabled the World Health Assembly to adopt the Pandemic Agreement last year, described by some observers as the Pandemic Agreement Lite precisely because it dodged the detail about PABS. Adopting a vague PABS annex and kicking further details down the road again – this time to the COP – might save face for multilateralism. But it simply delays the adoption of the Pandemic Agreement to yet another set of talks, leaving all member states vulnerable to public health emergencies in the meantime. Standard contracts? Developing countries want the annex to include a standard contract to govern access to biological material and digital sequencing, including benefit-sharing obligations. But Khokhar said that the IGWG Bureau and “other colleagues” have expressed that “a full standardised contract may not be the appropriate way”, as it is hard to predict what – if any – VTDs may be developed as a result. “Fair enough,” he said, adding that developing countries are prepared to explore the inclusion of a “basic contract” followed by a PABS contract, if a party has developed a medical countermeasure. “But what is their answer to this suggestion? Let’s have an open and a closed system. So, in this endeavour to try and find and create a multilateral system, we are actually going back to our national systems… What new system are we creating here? We’re creating nothing new?” For TWN, the lack of “contractually enforceable legal obligations for recipients of PABS materials and sequence information “will add to the legal uncertainty, as benefit-sharing will depend on the WHO concluding contracts with manufacturers. Namibian negotiator Taime Sylvester said that the funders of research in developing countries are “overwhelmingly high-income country governments and foundations”. They could “include PABS compliance as a condition of their grants,” said Sylvester, pointing to the example of the European Union’s Horizon Europe (2021–2027), its funding programme for research and innovation. This requires researchers to commit to Nagoya Protocol compliance, which mandates fair benefit-sharing from the use of genetic resources. Prospects for agreement Norwegian Health Counsellor Eirik Rodseth Bakka acknowledged that there are “significant outstanding issues, and I think as a collective, we do need to see significant progress next week”. However, he stressed that member states have the opportunity to “correct some of those inequities from the COVID-19 pandemic,” especially early access to vaccines for low- countries and lower-middle-income countries, and enabling “to the extent possible that there is more technology transfer and access to access to manufacturing capacity.” Karydakis expressed hope that “we will get this by May”, adding that talks may need to continue alongside the World Health Assembly in late May, the deadline for the annex. He also joked that night sessions were necessary to get people tired and hungry and “only able to leave the room when the deal is reached.” Sylvester said that Namibia believes that “a fair, functional, legally grounded PABS system” is possible and will assist both the global south and the global north need this functional system to succeed. So we we believe it. We believe that it can happen which is above and beyond, or we’re not asking any country to stand to a higher standard. We’re asking the same standards. Malaysia’s Hamza described the PABS system as “the litmus test for equity”. “We will have to see whether states will come in next week and design a PABS system that would actually make an improvement in the current status quo.When the Group for Equity gets together, the first thing we will assess is whether what we have agreed on, each paragraph, is really delivering equity.” Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Congress Presses RFK Jr on Whether New CDC Chief Can Act Independently on Vaccines 24/04/2026 Sophia Samantaroy Rear Admiral Erica Schwartz was nominated to lead the CDC. Schwartz would bring several decades of medical and public health experience in the US Navy, Public Health Service Commissioned Corps, and US Coast Guard, to an agency in turmoil. She has garnered bipartisan support for her nomination. US Health and Human Services Secretary Robert F Kennedy Jr offered contradictory responses that the country’s new leader of the Centers for Disease Control and Prevention (CDC) would be able to make decisions independent of political interference, especially around vaccines. The White House announced late last week its fourth pick in a year for CDC director, Dr Erica Schwartz, a medical doctor and former deputy surgeon general under the first Trump Administration. If approved by the Senate’s Health Committee, Schwartz would replace Dr Jay Bhattacharya, the NIH director and acting CDC director. “If Dr Schwartz is confirmed as CDC director, will you commit on the record, today, to implement whatever vaccine guidance she issues without interference?” asked Congressman Raul Ruiz, MD (CA-25) in a House hearing. “I’m not going to make that kind of commitment,” Kennedy said. “Because you probably won’t, you’ll fire her. Like you did with Dr Monarez, because you will not accept recommendations based on science,” Ruiz accused. Schwartz is a preventative medicine doctor and public health official with nearly three decades of service in the Navy, Public Health Commissioned Corps, the US Coast Guard. She has garnered bipartisan support – and applause from public health experts – for her nomination as a credible and service-oriented candidate. Kennedy faces questions about CDC independence HHS Secretary Robert F Kennedy Jr, responding to Senator Bill Cassidy’s concerns of political interference at the CDC. In his first appearance before Congress in months, Kennedy defended the CDC’s efforts and its response to contain the ongoing measles outbreak, saying the US “has done the best job in the world.” He also deflected blame for the over 2,000 measles cases in the past year across the country, saying “[i]t has nothing to do with me.” The secretary faced questions on abortion medication availability, the cost of healthcare, and research funding cuts, which the secretary admitted were “painful.” Senator Bill Cassidy (R-LA), a physician and chair of the Senate’s health committee has clashed with Kennedy over his vaccine stance. Kennedy’s hearing with the Senate Health, Education, Labor, and Pensions (HELP) committee this week saw similarly tense exchanges about the CDC director nominee. “I applaud the CDC director,” HELP chairman Senator Bill Cassify (R-LA) said. “She seems to be a qualified person.” But the Louisiana senator, a physician facing a tough reelection in the fall, noted that “there are currently political appointees at CDC who have worked to undermine trust and immunizations. “Will the new director, whoever she is, have the right to make decisions independently of those of political appointees and or replace them, or otherwise reassign them so they cannot continue to actively undermine trust in immunizations?” Cassidy asked. “Your characterization of the political appointees is wrong,” Kennedy said. When pressed by Cassidy, who again asked whether the CDC would be able to make independent decisions, Kennedy agreed. The Trump administration has apparently counseled Kennedy to tone down his anti-vaccine rhetoric as midterm elections approach this fall. Service in Navy, Coast Guard, Surgeon General’s office Schwartz served as a member of the Uniformed Public Health Service. Commissioned to the Navy in 1995 after receiving her medical degree, Schwartz served for 10 years with the branch before transitioning to the Coast Guard. During her tenure, she served as a Navy occupational medicine physician and head of preventative medicine at the Naval Medical Clinic in Annapolis. As Rear Admiral in the Coast Guard, Schwartz was responsible for the entire branches’ health care system, overseeing the Coast Guard’s “child care programs and food services delivery programs, ashore and afloat, and the Coast Guard’s Ombudsman, Substance Abuse, Health Promotion and Sexual Assault Prevention and Response programs,” according to her Coast Guard bio. Schwartz served under the first Trump administration as deputy surgeon general, overseeing COVID-19 vaccine deployment. She also instituted several key infectious disease prevention programs and policies for the Coast Guard, including those for anthrax, smallpox, influenza, and HIV. The nominee also holds degrees in law and public health. Schwartz’s focus on vaccine-preventable diseases, infectious diseases, and occupational health may put her at odds with the current HHS priorities, which have called for more research and attention for chronic diseases. “As a well-trained and credentialed physician and former Deputy Surgeon General, Erica Schwartz possesses the medical background and public health knowledge to understand that the Centers for Disease Control and Prevention must be guided by evidence-based science,” said Dr George C Benjamin, the American Public Health Association (APHA) CEO in a press statement. APHA has consistently criticized the Trump Administration’s public health actions, including changes to the childhood vaccination schedule and removing clean air protections. “Erica Schwartz is a credible CDC director. But she’ll need assurances against political interference & ongoing attacks on science and the CDC itself,” said Lawrence Gostin, distinguished professor at Georgetown University and Director of the O’Neill Institute for National and Global Health Law. But the global health security expert noted “the signs are not good. RFK may impose a leadership team & senior CDC officials are extreme MAHA advocates.” Gostin alluded to past interferences between HHS and CDC leadership in the childhood vaccine schedule, which was modified late last year. If confirmed, Schwartz would be responsible for adopting the controversial vaccine schedule recommended by the Secretary’s handpicked committee, also known as ACIP. Last June, Kennedy fired the entire panel of vaccine advisers, instead replacing them with vaccine skeptics. A federal judge has since blocked changes to the vaccine schedule, ruling that the removal of the original committee violated a law governing federal expert committees. Schwartz would also likely face pressure from Kennedy on vaccines, just as Susan Monarez, the first Senate-confirmed CDC director under the Trump administration publicly testified about. Monarez led the agency briefly in 2025, before being ousted by Kennedy Jr just 29 days into her tenure. In Senate testimony about her firing, Monarez told the Senate Health Committee members that she refused Kennedy’s requests to “replace evidence with ideology,” in pre-approving vaccine recommendation changes and in firing career public health officials. Mixed feelings from anti-vaccine advocates The percentage of American kindegartners who have been vaccinated against measles has declined in the past two decades. Some in anti-vaccine wings have expressed feelings of betrayal at Trump’s pick. In a social media post Nicholas Hulscher, an activist with the anti-vaccine advocacy organization the McCullough group, lamented the nomination. “Trump’s new CDC director pick, Erica Schwartz, forced smallpox, anthrax, and flu shots into our troops with threats and discipline for those who refused. She personally wrote and signed the DIRECT ORDERS making them MANDATORY for Coast Guard troops.” Others closer to Secretary Kennedy, including his former personal attorney Aaron Siri, also criticized Schwartz’s vaccine mandates when she served as Rear Admiral in the Coast Guard. “This agency does not need another cheerleader for industry; it needs a regulator over industry,” Siri said in a statement to Politico last week. The administration announced several other CDC leadership changes, including Sean Slovenski, a digital health administrator, as deputy director and chief operating officer; Dr Jennifer Shuford, commissioner at the Texas public health department, as chief medical officer and deputy director; and Dr Sara Brenner, who serves as FDA principal deputy commissioner, to be a senior adviser to Kennedy. Image Credits: HHS, CDC. New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New Chapter for Africa’s Malaria Response Through Accountability and Sovereignty 24/04/2026 Amma A Twum-Amoah , Joy Phumaphi & Michael Adekunle Charles The first two girls ever vaccinated with the malaria vaccine RTS,S in Ghana. The African Union Commission, the African Leaders Malaria Alliance (ALMA) and the RBM Partnership to End Malaria each play a distinct role in Africa’s malaria response, from continental policy direction to member state leadership and accountability, to coordination of the broader global and regional partnership. This World Malaria Day (25 April), we write together because the moment demands exactly that: global coordination, continental resolve, and sustained political leadership. This joint reflection is more than symbolic. It signals a renewed commitment to stronger coordination, more effective delivery, and shared accountability for results. This moment requires honesty. Yes, Africa has made remarkable progress against malaria, since 2000. More than 1.64 billion cases have been prevented and 12.4 million lives have been saved. Yet the trend is moving in the wrong direction. In 2024 alone, Africa recorded 270.8 million malaria cases and nearly 600,000 deaths. Most devastating of all, 75% of those deaths were children under five. The hard-won gains of the early 2000s have stalled, and with the continent is now off track to meet the targets of the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. This is not a moment for incrementalism. It is a moment for renewed political commitment from member states. An intensifying perfect storm Africa’s malaria response is being tested by a convergence of pressures: shrinking external financing, climate change, insecticide and drug resistance, and the growing burden of humanitarian crises. The global health financing landscape is shifting in ways that are structural, not cyclical. This is not a temporary disruption. The global health financing landscape is changing in ways that are structural, not cyclical. The era in which malaria control could rely heavily on external funding is coming to an end. For Africa, this is an inflection point. The question before us is clear: do we allow these changes to deepen vulnerability, or do we use them to build something stronger and more durable? Do we continue to depend on systems designed and financed elsewhere, or do we seize this moment to build a continent that controls malaria on its own terms, financed increasingly by its own resources, driven by its own institutions, and supported, rather than led, by global partners? This is the real challenge before us. And it is also the opportunity. Accountability for the ‘Big Push against Malaria’ Zambia started to roll out the malaria vaccine in December 2025. This baby is being vaccinated at the Lumezi Urban Clinic. The country is also rolling out a new tool to track its progress against malaria. In response to the rising malaria cases and associated deaths, at last year’s AU Summit, African Heads of State and Government endorsed the African Union Roadmap to 2030 and Beyond. This roadmap is not simply another declaration. It is an acceleration plan designed to get Africa back on track to meet the targets of the AU Catalytic Framework. At the same time, the RBM Partnership is stewarding the “Big Push against Malaria”, a new approach grounded in endemic country leadership, sustainable solutions, and health sovereignty. Its purpose is to align global, regional, and national actors behind country-defined priorities and nationally owned, optimised plans. A key shift is how we hold ourselves accountable to those commitments, especially at the national level. In February, Zambia became the first AU Member State to roll out a new monitoring and accountability approach aligned with this effort. Building on its existing malaria scorecard management tool, the country has enhanced how it tracks progress at national and subnational levels. To reflect the interconnected factors that influence malaria outcomes, this new approach expands coordination across sectors, engaging Ministries beyond health, such as finance, agriculture, water and sanitation, and environment. By strengthening existing systems rather than creating parallel ones, Zambia is demonstrating how accountability can be embedded into existing governance systems and how political commitments made at higher levels can be followed through to actual delivery. This is the kind of leadership Africa needs: practical, country-owned and measurable. Accountability needs strong, sovereign foundations Ghanaian President John Mahama welcoming delegates to the Africa Health Sovereignty Summit in August 2025, where countries committed more domestic finances to health. Accountability alone, however, will not carry this agenda. We need African health sovereignty. First, domestic financing must shift from aspiration to obligation. More than two decades after the Abuja Declaration, fewer than five countries have met the target of allocating at least 15% of annual national budgets to health. Malaria financing must be seen as an investment in national security, economic productivity and human development. Second, Africa must reduce its dependence on imported malaria commodities, diagnostics and medicines. A continent that bears the heaviest malaria burden should not remain dependent on external supply. We must manufacture in Africa, for Africa. The African Medicines Agency, the African Continental Free Trade Area, and Africa’s growing pharmaceutical capacity already provide a foundation. What is needed now is scale, speed and political backing. Third, surveillance and data systems must be treated as sovereign infrastructure. No country can eliminate malaria if it does not know where transmission is happening, how patterns are changing or which interventions are working. Surveillance is not a technical add-on. It is the backbone of a credible elimination strategy. As the Africa CDC strengthens continental health intelligence systems, malaria must be central to that architecture. Fourth, malaria elimination must also be fully integrated into primary health care. Universal health coverage and malaria elimination are not competing agendas. They reinforce one another. Every investment that strengthens local health systems, expands access to frontline services and improves continuity of care also strengthens the malaria response. The commitments already exist through the African Union’s Catalytic Framework to End HIV, TB and Eliminate Malaria in Africa by 2030. What is now required is financing that matches ambition and political follow-through that turns declarations into delivery. Malaria-free Africa is within reach A malaria-free Africa is within reach. Countries such as Algeria, Cabo Verde and Egypt have demonstrated what sustained commitment, political leadership and coordinated action can deliver. The progress proves that elimination is possible on the continent. But a malaria-free Africa is not a gift conferred by others, it is a condition created through sovereign investment, determined leadership, accountable systems and enduring institutions. The tools exist. The science is stronger than ever. The institutions are in place. What Africa needs now is the discipline to hold itself accountable and the resolve to act with urgency. Ending malaria is one of Africa’s greatest health opportunities. It is also one of the clearest proofs of what genuine self-determination in global health looks like. This is the new chapter before us. Africa must write it with accountability. Africa must finance it with sovereignty. And Africa must deliver it with leadership. Ambassador Amma A Twum-Amoah is the African Union Commissioner for Health, Humanitarian Affairs and Social Development. Dr Joy Phumaphi is executive secretary of the African Leaders Malaria Alliance (ALMA) and former Health Minister of Botswana. Dr Michael Adekunle Charles is CEO of the RBM Partnership to End Malaria Image Credits: Temwanani Mtonga/ Gavi, WHO/Fanjan Combrink. Posts navigation Older posts